Chemistry–A European Journal

Supporting Information

Catalytic Enantioselective Synthesis of Heterocyclic Vicinal Fluoroamines by Using Asymmetric Protonation: Method Development and Mechanistic Study**

Matthew W. Ashford,^[a] Chao Xu,^[a] John J. Molloy,^[a] Cameron Carpenter-Warren,^[a] Alexandra M. Z. Slawin,^[a] Andrew G. Leach,^{*[b]} and Allan J. B. Watson^{*[a]}

Table of Contents

1. General	S3
2. General Experimental Procedures	
3. Optimization of Reaction Conditions	
4. Catalyst ee vs. Product ee	
5. Mechanistic Study	
5.1 DFT Calculations	
5.2 HRMS Study	
5.2 Kinetic Isotope Effect Study	
6. Ramachandran Plots	
7. Characterization Data for Compounds	
8. References	
9. NMR Spectra	
10. X-Ray Data	

1. General

All reagents and solvents were obtained from commercial suppliers and were used without further purification unless otherwise stated. Purification was carried out according to standard laboratory methods.¹

1.1 Purification of Solvents

Dry THF for reactions were obtained from a PureSolv SPS-400-5 solvent purification system. Et₂O, EtOAc, and petroleum ether 40-60 $^{\circ}$ C for purification purposes were used as obtained from suppliers without further purification.

1.2 Experimental Details

Reactions were carried out using conventional glassware (preparation of intermediates), 2 mL HPLC vials, or in capped 5, 10, and 20 mL microwave vials. The glassware was oven-dried (150 °C) and purged with N₂ before use. Purging refers to a vacuum/nitrogen-refilling procedure. Prior to use, Mg turnings were oven-dried at 150 °C overnight. TRIP refers to 3,3'-bis(2,4,6-triisopropylphenyl)-1,1'-binaphthyl-2,2'-diyl hydrogenphosphate. Room temperature (rt) was generally *ca.* 18 °C. Reactions were carried out at elevated temperatures using a temperature-regulated hotplate/stirrer with a sand bath. Reactions were carried out at -10, -20, and -50 °C using an isopropanol bath cooled by a Thermo Haake EK90 cryocooler. Reactions were carried out at 0 °C using an ice/water bath.

1.3 Purification of Products

Thin layer chromatography was carried out using Merck silica plates coated with fluorescent indicator UV254. These were analyzed under 254 nm UV light, developed using potassium permanganate or vanillin solutions. Normal phase flash chromatography was carried out using ZEOprep 60 HYD 40-63 μ m silica gel.

1.4 Analysis of Products

Fourier Transformed Infra-Red (FTIR) spectra were obtained on a Shimadzu IRAffinity-1 machine. ¹⁹F NMR spectra were obtained on either a Bruker AV 400 spectrometer at 376 or 377 MHz, or a Bruker AV 500 spectrometer at 470 MHz, respectively. ¹¹B NMR spectra were obtained on a Bruker AV 400 spectrometer at 128 MHz. ¹H and ¹³C NMR spectra were obtained on either a Bruker AV 400 at 400 MHz and 101 MHz, respectively, or Bruker DRX 500 at 500 MHz and 126 MHz, respectively. Chemical shifts are reported in ppm and coupling constants are reported in Hz with CDCl₃ referenced at 7.26 (¹H) and 77.0 ppm (¹³C) and DMSO-*d*₆ referenced at 2.50 (¹H) and 39.5 (¹³C). ¹¹B NMR spectra are referenced to BF₃·Et₂O. Unless otherwise stated, *J* refers to ³*J*_{HH} and *J*_{CF} in ¹H and ¹³C NMR, respectively. High-resolution mass spectra were obtained either through analysis at the EPSRC UK National Mass Spectrometery Facility at Swansea University, or through analysis at the University of St Andrews. High performance liquid chromatography (HPLC) was performed on an Agilent 1200 series HPLC using a chiral stationary phase column (column, Daicel Co. CHIRALCEL OJ-H, or CHIRALPAK IA; eluent: *n*-hexane/*i*-PrOH). All solvents used were HPLC-grade solvents purchased from Fisher. The column employed and the respective solvent mixture are indicated for each experiment. Optical rotations were obtained on a Perkin Elmer Model 341 polarimeter.

2. General Experimental Procedures

General Procedure A: Aza-Michael reaction catalyzed using a chiral acid (THF as solvent). For example, preparation of 7a.



A 2 mL HPLC vial was charged with 2-(1-fluorovinyl)quinoline (17.3 mg, 0.10 mmol, 1.0 equiv), and (S)-TRIP catalyst (15.1 mg, 0.02 mmol, 20 mol%). The vial was then capped and purged with N₂ before adding THF (200 μ L, 0.5 M). The reaction mixture was cooled to -10 °C for 15 min before the addition of aniline (27 μ L, 0.30 mmol, 3.0 equiv). The resulting mixture was then allowed to stir at -10 °C for 3 d before being quenched by sat. aq. K₂CO₃ solution (2 mL). The phases were separated and the aqueous phase extracted with EtOAc (5 mL × 3). The organic phases were combined, dried over Na₂SO₄, filtered, and concentrated *in vacuo*. Purification of the crude *via* flash chromatography (silica gel, EtOAc:petroleum ether, 5:95 to 10:90) gave the desired product as a pale yellow oil (21.8 mg, 82%, 96:4 e.r.).

General Procedure B: Aza-Michael reaction catalyzed using a chiral acid (CPME as solvent). For example, preparation of 7b.



A 2 mL HPLC vial was charged with 2-(1-fluorovinyl)quinoline (17.3 mg, 0.10 mmol, 1.0 equiv), and (*S*)-TRIP catalyst (15.1 mg, 0.02 mmol, 20 mol%). The vial was then capped and purged with N₂ before adding CPME (200 μ L, 0.5 M). The reaction mixture was cooled to -20 °C for 15 min before the addition of 4-(methylthio)aniline (41.7 mg, 0.3 mmol, 3.0 equiv). The resulting mixture was then allowed to stir at -20 °C for 5 d before being quenched by sat. aq. K₂CO₃ solution (2 mL). The phases were separated and the aqueous phase extracted with EtOAc (5 mL × 3). The organic phases were combined, dried over Na₂SO₄, filtered, and concentrated *in vacuo*. Purification of the crude *via* flash chromatography (silica gel, EtOAc:petroleum ether, 5:95 to 10:90) gave the desired product as a pale yellow oil (29.0 mg, 93%, 97:3 e.r.).

General Procedure C: Hiyama coupling. For example, preparation of 5a.



Prepared according to adapted literature procedure.²

An oven dried, 20 mL microwave vial was charged with 2-bromoquinoline (207 mg, 1.00 mmol, 1.0 equiv), (1-fluorovinyl)(methyl)diphenylsilane (356 mg, 1.5 mmol, 1.5 equiv), $Pd(PPh_3)_4$ (57.8 mg, 0.05 mmol, 5 mol%), CuI (9.7 mg, 0.05 mmol, 5 mol%) and CsF (357 mg, 2.35 mmol, 2.35 equiv). The microwave vial was then capped and purged with N₂ before addition of DMF (10 mL, 0.1 M). The reaction mixture was then allowed to stir at rt for 3.5 h. The reaction was quenched with water (20 mL)

and diluted with Et_2O (20 mL). The organic phase was separated, washed with water (2 × 10 mL) and brine (10 mL), dried over Na₂SO₄, filtered, and concentrated *in vacuo*. Purification of the crude *via* flash chromatography (silica gel, Et_2O :petroleum ether, 1:99) gave the desired product as a pale yellow oil (161 mg, 93%).

General Procedure D: Catalyst e.r. vs product e.r.



A 2 mL HPLC vial was charged with 2-(1-fluorovinyl)quinoline (17.3 mg, 0.10 mmol, 1.0 equiv), and different ratios of (*S*)- and (*R*)-TRIP catalyst (15.1 mg, 0.02 mmol, 20 mol%) (cat. e.r.: 60:40, 70:30, 80:20, 90:10 and 100:0). The vial was then capped and purged with N₂ before adding THF (200 μ L, 0.5 M). The reaction mixture was cooled to -10 °C for 15 min before the addition of aniline (27 μ L, 0.30 mmol, 3.0 equiv). The resulting mixture was then allowed to stir at -10 °C for 3 d before being quenched by sat. aq. K₂CO₃ solution (1 mL). The phases were separated and the aqueous phase was extracted with EtOAc (10 mL × 3). The organic phases were combined, dried over Na₂SO₄, filtered, and concentrated *in vacuo*. The e.r. of the product was determined by HPLC with an internal standard.

General Procedure E: Kinetic isotope effect



A 2mL HPLC vial was charged with 2-(1-fluorovinyl)quinoline (17.3 mg, 0.10 mmol, 1.0 equiv), (S)-TRIP catalyst (15.1 mg, 0.02 mmol, 20 mol%), and aniline (27 μ L, 0.30 mmol, 3.0 equiv). The vial was then capped and purged with N₂ before adding *d*₈-THF (400 μ L, 0.25 M). The resulting mixture was then transferred into a 0.5mm NMR tubes (7 inch) and ¹⁹F NMR was taken every 6 min for a period of 5 h to allow the determination of the conversion.

3. Optimization of Reaction Conditions



Entry	Solvent	Concentration	Time	Catalyst	Cat. loading (mol%)	(°C)	Aniline (equiv)	% conv." (e.r.)
	THE	(M)	(n)	0	(11101770)	(0)	(•••••••)	
1	THF	0.5	48	9a		-20	3	0 ()
2	THF	0.5	48	9a	20	-20	3	40 (96:4)
3	THF	0.5	96	9a	20	-20	3	68 (97:3)
4	THF	0.25	48	9a	20	-20	3	28 (97:3)
5	THF	0.1	48	9a	20	-20	3	15 (98:2)
6	THF	0.5	48	9a	20	-20	5	48 (95:5)
7	THF	0.5	48	9a	20	-20	10	58 (95:5)
8	THF	0.5	48	9a	10	-20	3	37 (95:5)
9	THF	0.5	48	9b	20	-20	3	25 (88:12)
10	THF	0.5	48	9c	20	-20	3	11 (58:42)
11	THF	0.5	48	9d	20	-20	3	n.d. ()
12	THF	0.5	48	9e	20	-20	3	6 (55:45)
13	THF	0.5	48	9f	20	-20	3	n.d. ()
14	THF	0.5	48	9g	20	-20	3	10 (62:38)
15	THF	0.5	48	9h	20	-20	3	25 (25:75)
16	THF	0.5	48	9i	20	-20	3	28 (89:11)
17	THF	0.5	48	9j	20	-20	3	n.d. ()
18	THF	0.5	48	9a	20	-10	3	68 (96:4)
19	THF	0.5	72	9a	20	-10	3	82 ^b (96:4)
20	CPME	0.5	72	9a	20	-10	3	89 ^b (95:5)
21	hexane	0.5	72	9a	20	-10	3	98 (71:29)
22	toluene	0.5	72	9a	20	-10	3	95 (89:11)
23	Et ₂ O	0.5	72	9a	20	-10	3	94 (94:6)
24	CH_2Cl_2	0.5	72	9a	20	-10	3	70 (75:25)
25	CPME	0.5	120	9a	20	-20	3	81 (95:5)
26	CPME	0.5	120	9a	10	-20	3	68 (93:7)

^a Determined by HPLC analysis with internal standard; ^b isolated yield.

4. Catalyst ee vs. Product ee



A series of mixtures of (*R*)-TRIP and (*S*)-TRIP were made in varying ratios. Reactions were carried out following General Procedure D, the enantioenrichment of each product was determined by HPLC analysis (Chiralpak IA, hexane/*i*-PrOH = 90/10, flow rate 0.5 mL/min, λ = 250 nm), t_r (major) = 23.4 min, t_r (minor) = 25.6 min. R² suggests no non-linear effects in these initial experiments.



5. Mechanistic Study 5.1 DFT Calculations

Conformation Generation

The starting geometry for the catalyst was adapted from the crystal structure of pyridinium complex in the crystal structure with Cambridge database code CAZKEU.³ It was assumed that the NH-O=P interaction present in this and all comparable crystal structures was retained and conformations of key structures were generated manually and where they yielded an optimized structure they are given below.

To study the conformational space of the bound complexes, we considered complexes with the catalyst bearing a proton on either of the two protruding phosphate oxygens (distal and proximal) and assumed a hydrogen bond with the quinoline nitrogen to be a critical interaction. Given this constraint, a full conformational exploration of both enantiomers of the product complex was undertaken. Two orientations of the quinoline ring were considered: one in which a secondary interaction between the the distal phosphate oxygen and the CH *peri* to the quinoline nitrogen was in place and one in which a 180° rotation about the POH^{\cdots}N_{quinoline} hydrogen bond takes place. All rotamers of the CHFCH₂NHPh sidechain that could be sterically accommodated by the catalyst were attempted and *i*-Pr groups at ortho positions in the catalyst were retained in their preferred conformation while the *i*-Pr at the para position was adjusted to minimise clashing with the bound species (the geom=nocrowd option in Gaussian 09⁴ was used in order to permit the relaxation of species featuring a small amount of steric clashing).

Calculations involving complexes containing chiral phosphoric acids

All frequency and geometry calculations were carried out using hybrid QM/MM calculations using the ONIOM method with B3LYP functional with the 6-31G** basis set for all atoms arising from aniline or quinoline and the PO₄H from the catalyst, and UFF is applied to the remainder of the catalyst. Additional single-point energy calculations were carried out on the previously optimised geometries using the M06-2X functional with the 6-31G** basis set employing a PCM solvation in diethyl ether and using an ultrafine grid. All calculations using the B3LYP, UFF or M06-2X functional have been performed using Gaussian 09.⁴

Calculations involving complexes not containing chiral phosphoric acids

All frequency and geometry calculations were carried out using the B3LYP functional with the 6-31G** basis set. Additional single-point energy calculations were carried out on the previously optimised geometries using the M06-2X functional with the 6-31G** basis set employing a PCM solvation in diethyl ether and using an ultrafine grid. All calculations using the B3LYP or M06-2X functional have been performed using Gaussian 09.⁴

Free energy calculations

Free energies are calculated from the generated electronic energies using the GoodVibes program (version 2.0.3)⁵ with a standard state of 1M concentration and temperature of 253K.

Transition State Generation

All of the optimized complexes that were within 3 kcal mol^{-1} of the complex with the lowest energy were then subjected to a scan in which the proton at the stereocentre was moved towards either, the aniline nitrogen, the nearest (proximal) O=P or the furthest (distal) O=P. Each of these scans were then

used to initiate transition state optimizations. Subsequently, the lowest energy transition state structure was the starting point for a limited exploration of each of the steps that occurs prior to the stereoselectivity-determining step.

5.1.1 Reaction Profile - 5a

Free energy profile comparison (ONIOM (B3LYP/6-31G**:UFF), [single-point energy M06-2X/6-31G**(+PCM for Et₂O)]).



5.1.2 Reaction Profile – S1 (Phenyl System)

The reaction of compound S1 studied previously was revisited with the insights provided by the calculations described in the main text.



Free energy profile comparison (ONIOM (B3LYP/6-31G**:UFF), [single-point energy M06-2X/6-31G**(+PCM for Et₂O)]).



5.1.2 Reaction Profile – RDS Energy profile

A series of calculations, demonstrating the difference in energy for the RDS of different substrates. Free energy profile comparison (ONIOM (B3LYP/6-31G**:UFF), [single-point energy M06-2X/6-31G**(+PCM for Et₂O)]).



5.1.5 Background Reaction Profile - 5a & 10

A series of calculations, demonstrating the high energy barrier RDS for the uncatalyzed reaction, and decrease in the vinyl CF₃ system. Free energy profile comparison (ONIOM (B3LYP/6-31G**:UFF), [single-point energy M06-2X/6-31G**(+PCM for Et₂O)]).



5.2 HRMS Study

A series of reactions were analyzed by ESI analysis. Results suggest the product 7a has the largest affinity towards CPA 9a as compared to aniline 8 and quinoline 5a.



5.3 Kinetic Isotope Effect Study5.3.1 Kinetic Isotope Effect of Aniline

Data was obtained according to General Procedure E using aniline.



5.3.2 Kinetic Isotope Effect of *D*₂-Aniline

Data was obtained according to General Procedure E using D_2 -aniline for 10 h.



5.3.3 Kinetic Isotope Effect of ¹⁵N-Aniline

Data was obtained according to General Procedure E using $^{15}\!N\textsc{-aniline}$.



6. Ramachandran Plots

Ramachandran plots were computed at the M06-2X/6-31+G** level of theory. Calculations were performed in Gaussian09 using the modified redundant coordinate facility with dihedral angles being moved in 15° increments. Energy in kcal mol⁻¹.

6.1 Ramachandran Plot for Compound 9a



6.2 Ramachandran Plot for Compound 16



6.3 Ramachandran Plot for N-(2-(Quinolin-2-yl)ethyl)aniline



7. Characterization Data for Compounds

2-Bromo-3-methylquinoline S3



Prepared according to literature procedures.^{6,7}

An oven-dried, 250 mL round bottomed flask was charged with 3-methylquinoline (1.34 mL, 10.0 mmol, 1.0 equiv). The vessel was sealed and purged with N₂. CH_2Cl_2 (50 mL, 0.2 M) was added to the vessel and the mixture was stirred at 0 °C for 15 min before the addition of *m*CPBA (1.91 g, 11.0 mmol, 1.1 equiv). The reaction was left to stir at rt for 16 h. The mixture was then diluted with CH_2Cl_2 (50 mL), and washed with aq. KOH 6 M solution (3 × 50 mL). The organic layer was collected, dried over Na₂SO₄, filtered, and concentrated *in vacuo*.

NB. Calculations based upon quantitative conversion to 2-bromo-3-methylquinoline 1-oxide in the previous step. An oven-dried, 250 mL round bottomed flask was charged with the crude 3-methylquinoline *N*-oxide (10.0 mmol, 1.0 equiv) and POBr₃ (8.60 g, 30.0 mmol, 3.0 equiv). The vessel was sealed and purged with N₂. Dry CH₂Cl₂ (50 mL, 0.2 M) and dry DMF (1.16 mL, 1.50 mmol, 1.5 equiv) were added. The reaction was left to stir at rt for 4 h. Sat. aq, Na₂SO₄ solution was added slowly until the pH was 7-8. The layers in the resulting mixture were separated and the aqueous was extracted with CH₂Cl₂ (3×50 mL). The organic phases were combined, dried over Na₂SO₄, filtered, and concentrated *in vacuo*. Purification of the crude product *via* flash chromatography (silica gel, EtOAc:petroleum ether, 1:99) gave the desired product as a white solid (506 mg, 23%).

¹**H NMR (500 MHz, CDCl₃):** δ 8.00 (d, *J* = 8.5 Hz, 1H), 7.90 (s, 1H), 7.71 (d, *J* = 8.1 Hz, 1H), 7.68 – 7.62 (m, 1H), 7.58 – 7.47 (m, 1H), 2.52 (d, *J* = 1.1 Hz, 3H).

¹³C NMR (126 MHz, CDCl₃): δ 147.1, 145.6, 137.1, 132.4, 129.6, 128.4, 127.8, 127.2, 127.0, 22.5.

Spectroscopic data in agreement with literature values.⁶

2-Bromo-6-fluoroquinoline S4



Prepared according to a literature procedure.⁶

An oven-dried, 10 mL microwave vial was charged with 6-fluoroquinolin-2(1H)-one (226 mg, 1.00 mmol, 1.0 equiv) and POBr₃ (56.2 mg, 1.10 mmol, 1.1 equiv). The vessel was capped and purged with N₂. The mixture was heated to 140 °C for 3 h, then cooled to rt and poured over ice. The resulting precipitate was collected, washed with petroleum ether and dried *in vacuo* to give the desired product as a pale brown solid (114 mg, 50%).

¹**H NMR (400 MHz, CDCl₃):** δ 8.04 (dd, *J* = 9.2, 5.2 Hz, 1H), 7.96 (d, *J* = 8.6 Hz, 1H), 7.54 (d, *J* = 8.6 Hz, 1H), 7.50 (td, *J* = 8.8, 2.8 Hz, 1H), 7.43 (dd, *J* = 8.6, 2.8 Hz, 1H).

¹³C NMR (126 MHz, CDCl₃): δ 160.7 (d, ¹*J* = 249.5 Hz), 145.7, 141.1, 137.8 (d, ⁴*J* = 5.2 Hz), 131.3 (d, ³*J* = 9.3 Hz), 127.8 (d, ³*J* = 10.3 Hz), 126.7, 120.9 (d, ²*J* = 25.5 Hz), 111.2 (d, ²*J* = 22.2 Hz).

¹⁹F NMR (376 MHz, CDCl₃): δ –111.94.

Spectroscopic data in agreement with literature values.⁷

2,6-Dibromoquinoline **S5**



Prepared according to a literature procedure.⁶

An oven-dried, 10 mL microwave vial was charged with 6-bromoquinolin-2(1H)-one (251 mg, 1.13 mmol, 1.13 equiv) and POBr₃ (287 mg, 1.00 mmol, 1.0 equiv). The vessel was capped and purged with N₂. The mixture was heated to 140 °C for 3 h, then cooled to rt and poured over ice. The resulting precipitate was collected, washed with petroleum ether and dried *in vacuo* to give the desired product as a brown solid (178 mg, 62%).

¹**H NMR (500 MHz, CDCl₃):** δ 7.98 (d, *J* = 2.2 Hz, 1H), 7.91 (dd, *J* = 8.7, 2.0 Hz, 2H), 7.80 (dd, *J* = 8.9, 2.2 Hz, 1H), 7.55 (d, *J* = 8.6 Hz, 1H).

¹³C NMR (126 MHz, CDCl₃): δ 147.3, 142.4, 137.4, 134.2, 130.5, 129.9, 128.2, 126.9, 121.2.

Spectroscopic data in agreement with literature values.⁶

2-(1-Fluorovinyl)quinoline 5a



Prepared according to General Procedure C using 2-bromoquinoline (207 mg, 1.00 mmol, 1.0 equiv), (1-fluorovinyl)(methyl)diphenylsilane (356 mg, 1.50 mmol, 1.5 equiv), $Pd(PPh_3)_4$ (59.0 mg, 0.05 mmol, 5 mol%), CuI (9.7 mg, 0.05 mmol, 5 mol%), CsF (364 mg, 2.35 mmol, 2.35 equiv), and DMF (10 mL, 0.1 M). The reaction mixture was subjected to the purification outlined in the General Procedure C (silica gel, Et₂O:petroleum ether, 1:99) to afford the desired product as a pale yellow oil (161 mg, 93%).

 v_{max} (film): 3056, 2926, 1654, 1284, 1108, 834, 758 cm⁻¹.

¹**H** NMR (400 MHz, CDCl₃): δ 8.13 (d, J = 8.6 Hz, 1H), 8.10 (d, J = 8.5 Hz, 1H), 7.81 (dd, J = 8.1, 0.9 Hz, 1H), 7.73 (ddd, J = 8.4, 6.9, 1.4 Hz, 1H), 7.69 (dd, J = 8.6, 1.2 Hz, 1H), 7.54 (ddd, J = 8.1, 6.9, 1.1 Hz, 1H), 5.87 (dd, ³ $_{JHF}$ = 48.6 Hz, ² $_{JHH}$ = 2.9 Hz, 1H), 5.14 (dd, ³ $_{JHF}$ = 16.4 Hz, ² $_{JHH}$ = 2.9 Hz, 1H).

¹³C NMR (126 MHz, CDCl₃): δ 162.3 (d, ¹*J* = 251.2 Hz), 150.1 (d, ²*J* = 35.4 Hz), 147.9 (d, ⁴*J* = 3.8 Hz), 136.9, 130.0, 129.8, 128.0, 127.6, 127.1, 116.8 (d, ³*J* = 4.7 Hz), 93.8 (d, ²*J* = 18.4 Hz).

¹⁹F NMR (376 MHz, CDCl₃): δ –114.28.

HRMS (ESI): exact mass calculated for $[M+H]^+$ (C₁₁H₉NF) requires m/z 174.0714, found m/z 174.0712.

2-(1-Fluorovinyl)-3-methylquinoline 5b



Prepared according to General Procedure C using 2-bromo-3-methylquinoline (99.5 mg, 0.45 mmol, 1.0 equiv), (1-fluorovinyl)(methyl)diphenylsilane (164 mg, 0.675 mmol, 1.5 equiv), Pd(PPh₃)₄ (520 mg, 0.45 mmol, 1.0 equiv), CuI (85.7 mg, 0.45 mmol, 1.0 equiv), CsF (161 mg, 1.06 mmol, 2.35 equiv), and DMF (4.5 mL, 0.1 M). The reaction mixture was subjected to the purification outlined in General Procedure C (silica gel, Et₂O:petroleum ether, 1:99) to afford the desired product as a pale yellow oil (75.4 mg, 90%).

υ_{max} (film): 2361, 2342, 1655, 1493, 1447, 1327, 1273, 1184, 1138, 1065, 930, 903, 860, 791, 756, 729 cm⁻¹.

¹**H NMR (500 MHz, CDCl₃):** δ 8.08 (dd, J = 8.4, 1.3 Hz, 1H), 7.97 (s, 1H), 7.75 (dd, J = 8.2, 1.5 Hz, 1H), 7.67 (ddd, J = 8.4, 6.8, 1.5 Hz, 1H), 7.53 (ddd, J = 8.1, 6.8, 1.2 Hz, 1H), 5.37 (dd, ³ J_{HF} = 48.2 Hz, ² J_{HH} = 3.0 Hz, 1H), 5.19 (dd, ³ J_{HF} = 16.8 Hz, ² J_{HH} = 3.0 Hz, 1H), 2.60 (d, J = 4.9 Hz, 3H).

¹³C NMR (126 MHz, CDCl₃): δ 163.9 (d, ¹*J* = 256.3 Hz), 151.2 (d, ²*J* = 32.3 Hz), 146.2, 146.2, 137.6, 129.6, 129.2, 128.4, 127.5, 126.8, 96.3 (d, ²*J* = 19.2 Hz), 20.0 (d, ⁴*J* = 7.6 Hz).

¹⁹F NMR (470 MHz, CDCl₃): δ –99.90.

HRMS (ESI): exact mass calculated for $[M+H]^+$ (C₁₂H₁₁FN) requires m/z 188.0870, found m/z 188.0866.

6-Fluoro-2-(1-fluorovinyl)quinoline 5c



Prepared according to General Procedure C using 6-fluoro-2-bromoquinoline (150 mg, 0.664 mmol, 1.0 equiv), (1-fluorovinyl)(methyl)diphenylsilane (241 mg, 0.995 mmol, 1.5 equiv), Pd(PPh₃)₄ (38.3 mg, 0.033 mmol, 5 mol%), CuI (6.3 mg, 0.033 mmol, 5 mol%), CsF (237 mg, 1.56 mmol, 2.35 equiv), and DMF (6.6 mL, 0.1 M). The reaction mixture was subjected to the purification outlined in General Procedure C (silica gel, Et₂O:petroleum ether, 1:99) to afford the desired product as a pale yellow oil (84.0 mg, 66%).

 v_{max} (film): 1657, 1626, 1603, 1558, 1501, 1481, 1379, 1304, 1285, 1244, 1221, 1144, 1101, 916, 866, 829 cm⁻¹.

¹**H** NMR (400 MHz, CDCl₃): δ 8.12 (d, J = 8.7 Hz, 1H), 8.08 (dd, J = 9.3, 5.3 Hz, 1H), 7.68 (d, J = 8.7 Hz, 1H), 7.49 (td, J = 8.9, 2.8 Hz, 1H), 7.40 (dd, J = 8.7, 2.9 Hz, 1H), 5.84 (dd, ³ $J_{\rm HF}$ = 48.6 Hz, ² $J_{\rm HH}$ = 3.0 Hz, 1H), 5.13, (dd, ³ $J_{\rm HF}$ = 16.4 Hz, ² $J_{\rm HH}$ = 3.1 Hz, 1H).

¹³C NMR (126 MHz, CDCl₃): δ 162.0 (d, ¹*J* = 251.0 Hz), 160.8 (d, ¹*J* = 249.4 Hz), 149.6, (dd, ²*J* = 35.8, 3.1 Hz), 145.0 (d, ⁴*J* = 4.0 Hz), 136.4 (d, ³*J* = 6.6 Hz), 132.3 (d, ³*J* = 9.1 Hz), 128.6 (d, ³*J* = 10.1 Hz), 120.5 (d, ²*J* = 26.0 Hz), 117.6 (d, ⁴*J* = 4.7 Hz), 110.6 (d, ²*J* = 21.8 Hz), 93.8 (d, ²*J* = 18.5 Hz).

¹⁹F NMR (376 MHz, CDCl₃): δ –112.23, –114.42.

HRMS (ESI): exact mass calculated for $[M+H]^+$ (C₁₁H₈F₂N) requires m/z 192.0619, found m/z 192.0618.

6-Bromo-2-(1-fluorovinyl)quinoline 5d



Prepared according to General Procedure C using 2,6-dibromoquinoline (259 mg, 0.90 mmol, 1.0 equiv), (1-fluorovinyl)(methyl)diphenylsilane (328 mg, 1.38 mmol, 1.5 equiv), Pd(PPh₃)₄ (52.0 mg, 0.045 mmol, 5 mol%), CuI (8.6 mg, 0.045 mmol, 5 mol%), CsF (322 mg, 2.12 mmol, 2.35 equiv), and DMF (9 mL, 0.1 M). The reaction mixture was subjected to the purification outlined in General Procedure C (silica gel, Et₂O:petroleum ether, 1:99) to afford the desired product as a pale yellow solid (183 mg, 81%).

 v_{max} (film): 1659, 1595, 1489, 1283, 1190, 1107, 920, 874, 827 cm⁻¹.

¹**H NMR (400 MHz, CDCl₃):** δ 8.11 (d, J = 8.6 Hz, 1H), 7.97 (d, J = 2.2 Hz, 1H), 7.95 (d, J = 9.0 Hz, 1H), 7.78 (dd, J = 9.0, 2.2 Hz, 1H), 7.70 (dd, J = 8.7, 1.3 Hz, 1H), 5.87 (dd, ³ J_{HF} = 48.5 Hz, ² J_{HH} = 3.1 Hz, 1H), 5.16 (dd, ³ J_{HF} = 16.3 Hz, ² J_{HH} = 3.1 Hz, 1H).

¹³C NMR (126 MHz, CDCl₃): δ 161.9 (d, ¹*J* = 251.1 Hz), 150.5 (d, ²*J* = 35.6 Hz), 146.5 (d, ⁴*J* = 4.0 Hz), 136.1, 133.7, 131.5, 129.7, 129.1, 121.2, 117.8 (d, ³*J* = 4.6 Hz), 94.4 (d, ²*J* = 18.3 Hz).

¹⁹F NMR (376 MHz, CDCl₃): δ –114.60.

HRMS (ESI): exact mass calculated for $[M+H]^+$ (C₁₁H₈BrFN) requires *m/z* 251.9819, found *m/z* 251.9816.

4-Bromo-2-(1-fluorovinyl)quinoline 5e



Prepared according to General Procedure C using 2,4-dibromoquinoline (259 mg, 0.90 mmol, 1.0 equiv), (1-fluorovinyl)(methyl)diphenylsilane (328 mg, 1.35 mmol, 1.5 equiv), Pd(PPh₃)₄ (52.0 mg, 0.045 mmol, 5 mol%), CuI (8.6 mg, 0.045 mmol, 5 mol%), CsF (322mg, 2.12 mmol, 2.35 equiv), and DMF (9 mL, 0.1 M). The reaction mixture was subjected to the purification outlined in General Procedure C (silica gel, Et₂O:petroleum ether, 1:99) to afford the desired product as a pale yellow solid (105 mg, 42%).

 v_{max} (film): 2357, 1578, 1547, 1491, 1404, 1339, 1265, 1251, 1148, 1105, 928 cm⁻¹.

¹**H NMR (500 MHz, CDCl₃):** δ 8.12 (dd, J = 8.5, 1.4 Hz, 1H), 8.05 (dd, J = 8.5, 1.2 Hz, 1H), 7.94 (d, J = 1.2 Hz, 1H), 7.74 (ddd, J = 8.4, 6.8, 1.4 Hz, 1H), 7.60 (ddd, J = 8.2, 6.8, 1.2 Hz, 1H), 5.89 (dd, ³ $J_{\rm HF}$ = 48.4 Hz, ² $J_{\rm HH}$ = 3.1 Hz, 1H), 5.16 (dd, ³ $J_{\rm HF}$ = 16.2 Hz, ² $J_{\rm HH}$ = 3.1 Hz, 1H).

¹³C NMR (126 MHz, CDCl₃): δ 161.0 (d, ¹*J* = 251.5 Hz), 149.8 (d, ²*J* = 36.1 Hz), 148.3 (d, ⁴*J* = 4.0 Hz), 135.0 (d, ⁴*J* = 1.7 Hz), 130.9, 130.2, 128.3, 127.5, 126.7, 120.9 (d, ³*J* = 5.1 Hz), 94.7 (d, ²*J* = 17.9 Hz).

¹⁹F NMR (470 MHz, CDCl₃): δ –114.71.

HRMS (ESI): exact mass calculated for $[M+H]^+$ (C₁₁H₈BrFN) requires m/z 251.9819, found m/z 251.9817.

2-(1-Fluorovinyl)quinoxaline 5f



Prepared according to General Procedure C using 2-bromoquinoxaline (174 mg, 1.00 mmol, 1.0 equiv), (1-fluorovinyl)(methyl)diphenylsilane (363 mg, 1.50 mmol, 1.5 equiv), Pd(PPh₃)₄ (57.8 mg, 0.05 mmol, 5 mol%), CuI (6.6 mg, 0.05 mmol, 5 mol%), CsF (448 mg, 2.35 mmol, 2.35 equiv), and DMF (10 mL, 0.1 M). The reaction mixture was subjected to the purification outlined in General Procedure C (silica gel, Et₂O:petroleum ether, 1:99) to afford the desired product as a pale yellow solid (158 mg, 91%).

 v_{max} (film): 1655, 1506, 1489, 1364, 1341, 1105, 968, 924, 874, 764, 743 cm⁻¹.

¹**H NMR (400 MHz, CDCl₃):** δ 9.13 (s, 1H), 8.16 – 8.07 (m, 2H), 7.87 – 7.74 (m, 2H), 5.92 (dd, ³*J*_{HF} = 48.2 Hz, ²*J*_{HH} = 3.4 Hz, 1H), 5.27 (dd, ³*J*_{HF} = 16.5 Hz, ²*J*_{HH} = 3.4 Hz, 1H).

¹³C NMR (126 MHz, CDCl₃): δ 160.7 (d, ¹*J* = 250.8 Hz), 145.0 (d, ²*J* = 34.0 Hz), 142.6, 141.9, 141.3 (d, ³*J* = 5.3 Hz), 130.9, 130.7, 129.8, 129.4, 95.9 (d, ²*J* = 17.3 Hz).

¹⁹F NMR (376 MHz, CDCl₃): δ –116.24.

HRMS (ESI): exact mass calculated for $[M+H]^+$ (C₁₀H₈FN₂) requires m/z 175.0666, found m/z 175.0665.

2-(1-Fluorovinyl)benzo[d]thiazole 5g



Prepared according to General Procedure C using 2-Bromobenzothiazole (214 mg, 1.00 mmol, 1.0 equiv), (1-fluorovinyl)(methyl)diphenylsilane (356 mg, 1.50 mmol, 1.5 equiv), Pd(PPh₃)₄ (1.16 g, 1.00 mmol, 1.0 equiv), CuI (132 mg, 1.00 mmol, 1.0 equiv), CsF (364 mg, 2.40 mmol, 2.4 equiv), and DMF (10 mL, 0.1 M). The reaction mixture was subjected to the purification outlined in General Procedure C (silica gel, Et₂O:petroleum ether, 1:99) to afford the desired product as a pale yellow solid (73.8 mg, 42%).

 v_{max} (film): 2955, 2926, 2853, 1647, 1558, 1435, 1314, 1290, 1261, 1092, 760, 729, 700 cm⁻¹.

¹**H NMR (500 MHz, CDCl₃):** δ 8.08 (d, J = 8.2 Hz, 1H), 7.92 (d, J = 8.0 Hz, 1H), 7.64 – 7.36 (m, 3H), 5.74 (dd, ${}^{3}J_{\text{HF}}$ = 47.1 Hz, ${}^{2}J_{\text{HH}}$ = 3.7 Hz, 1H), 5.21 (dd, ${}^{3}J_{\text{HF}}$ = 15.5 Hz, ${}^{2}J_{\text{HH}}$ = 3.8 Hz, 1H).

¹³C NMR (126 MHz, CDCl₃): δ 159.9 (d, ²*J* = 39.3 Hz), 157.3 (d, ¹*J* = 247.7 Hz), 153.5 (d, ⁴*J* = 2.0 Hz), 135.0, 126.8, 126.1, 123.8, 121.9, 95.5 (d, ²*J* = 17.2 Hz).

¹⁹F NMR (470 MHz, CDCl₃): δ –106.57.

HRMS (ESI): exact mass calculated for $[M+H]^+$ (C₉H₇FNS) requires m/z 180.0278, found m/z 180.0277.

Methyl 6-(1-fluorovinyl)nicotinate 5h



Prepared according to General Procedure C using 6-bromonicotinate (216 mg, 1.00 mmol, 1.0 equiv), (1-fluorovinyl)(methyl)diphenylsilane (356 mg, 1.50 mmol, 1.5 equiv), $Pd(PPh_3)_4$ (59.0 mg, 0.05 mmol, 5 mol%), CuI (9.7 mg, 0.05 mmol, 5 mol%), CsF (364 mg, 2.40 mmol, 2.4 equiv), and DMF (10 mL, 0.1 M). The reaction mixture was subjected to the purification outlined in General Procedure C (silica gel, Et₂O:petroleum ether, 1:99) to afford the desired product as a pale yellow solid (164 mg, 91%).

 v_{max} (film): 1722, 1655, 1593, 1560, 1437, 1366, 1287, 1273, 1196, 1130, 1101, 1022, 920, 897, 858, 789, 733 cm⁻¹.

¹**H** NMR (400 MHz, CDCl₃): δ 9.14 – 9.13 (m, 1H), 8.31 (dd, J = 8.2, 2.1 Hz, 1H), 7.59 (d, J = 7.9 Hz, 1H), 5.84 (dd, ${}^{3}J_{\text{HF}}$ = 48.5 Hz, ${}^{2}J_{\text{HH}}$ = 2.9 Hz, 1H), 5.11 (dd, ${}^{3}J_{\text{HF}}$ = 16.3 Hz, ${}^{2}J_{\text{HH}}$ = 2.9 Hz, 1H), 3.94 (s, 3H).

¹³C NMR (126 MHz, CDCl₃): δ 165.4, 161.3 (d, ¹*J* = 249.3 Hz), 153.3 (d, ²*J* = 36.8 Hz), 150.8 (d, ⁴*J* = 4.5 Hz), 138.2 (d, ⁴*J* = 1.8 Hz), 125.8, 118.2 (d, ³*J* = 4.5 Hz), 95.2 (d, ²*J* = 17.6 Hz), 52.6.

¹⁹F NMR (376 MHz, CDCl₃): δ –115.94.

HRMS (ESI): exact mass calculated for $[M+H]^+$ (C₉H₉FNO₂) requires m/z 182.0612, found m/z 182.0610.

1-(1-Fluorovinyl)isoquinoline 5i



Prepared according to General Procedure C using 1-bromoisoquinoline (207 mg, 1.00 mmol, 1.0 equiv), (1-fluorovinyl)(methyl)diphenylsilane (356 mg, 1.50 mmol, 1.5 equiv), Pd(PPh₃)₄ (59.0 mg, 0.05 mmol, 5 mol%), CuI (9.7 mg, 0.05 mmol, 5 mol%), CsF (364 mg, 2.40 mmol, 2.4 equiv), and DMF (10 mL, 0.1 M). The reaction mixture was subjected to the purification outlined in General Procedure C (silica gel, Et₂O:petroleum ether, 1:99) to afford the desired product as a pale yellow oil (171 mg, 99%).

υ_{max} (film): 1657, 1622, 1584, 1557, 1393, 1298, 1250, 1215, 1175, 1153, 1140, 926, 858, 827, 748, 685, 579 cm⁻¹.

¹**H** NMR (400 MHz, CDCl₃): δ 8.53 (d, J = 5.6 Hz, 1H), 8.37 (d, J = 8.6 Hz, 1H), 7.83 (d, J = 8.2 Hz, 1H), 7.76 – 7.65 (m, 2H), 7.61 (ddd, J = 8.2, 6.9, 1.2 Hz, 1H), 5.50 – 5.19 (m, 2H).

¹³C NMR (126 MHz, CDCl₃): δ 163.0 (d, ¹*J* = 256.4 Hz), 151.0 (d, ²*J* = 31.1 Hz), 141.9, 136.9, 130.5, 128.0 (d, ⁴*J* = 1.9 Hz), 127.2, 126.3 (d, ³*J* = 9.7 Hz), 126.0 (d, ⁴*J* = 2.3 Hz), 122.2, 97.3 (d, ²*J* = 19.2 Hz).

¹⁹F NMR (376 MHz, CDCl₃): δ –97.19.

HRMS (ESI): exact mass calculated for $[M+H]^+$ (C₁₁H₉FN) requires m/z 174.0714, found m/z 174.0710.

4-(1-Fluorovinyl)quinoline 5j



Prepared according to General Procedure C using 4-bromoquinoline (208 mg, 1.00 mmol, 1.0 equiv), (1-fluorovinyl)(methyl)diphenylsilane (356 mg, 1.50 mmol, 1.5 equiv), Pd(PPh₃)₄ (57.8 mg, 0.05 mmol, 5 mol%), CuI (9.7 mg, 0.05 mmol, 5 mol%), CsF (364 mg, 2.40 mmol, 2.4 equiv), and DMF (10 mL, 0.1 M). The reaction mixture was subjected to the purification outlined in General Procedure C (silica gel, Et₂O:petroleum ether, 1:99) to afford the desired product as a pale yellow oil (82.1 mg, 47%).

NB. Due to the reactive nature of this compound, an analytically pure sample was not obtained, data reported as observed. The compound was used directly in the next step.

 v_{max} (film): 2959, 2928, 2870, 1659, 1578, 1558, 1508, 1493, 1462, 1362, 1315, 1282, 1258, 1180, 1153, 926, 849, 764 cm⁻¹.

¹**H NMR (400 MHz, CDCl₃):** δ 8.93 (d, J = 4.5 Hz, 1H), 8.23 – 8.15 (m, 2H), 7.79 – 7.73 (m, 1H), 7.67 – 7.58 (m, 1H), 7.49 (dd, J = 4.4, 1.1 Hz, 1H), 5.30 (dd, ³ J_{HF} = 16.7 Hz, ² J_{HH} = 3.4 Hz, 1H), 5.09 (dd, ³ J_{HF} = 47.9 Hz, ² J_{HH} = 3.4 Hz, 1H).

¹³C NMR (126 MHz, CDCl₃): δ 162.5, 160.5, 149.9, 149.9, 148.9, 148.7, 138.5, 138.3, 134.5, 134.1, 130.6, 130.1, 129.9, 128.1, 127.6, 127.0, 125.4, 125.4, 125.3, 125.1, 120.4, 97.7, 97.5, 85.5, 85.1, 82.9. *NB*. *J*_{CF} not indicated due to overlap of impurities.

¹⁹F NMR (376 MHz, CDCl₃): δ –92.69.

HRMS (ESI): exact mass calculated for $[M+H]^+$ (C₁₁H₉FN) requires m/z 174.0714, found m/z 174.0709.

8-Chloro-2-(1-fluorovinyl)quinoline 5k



Prepared according to General Procedure C using 2-bromo-8-chloroquinoline (121 mg, 0.50 mmol, 1.0 equiv), (1-fluorovinyl)(methyl)diphenylsilane (182 mg, 0.75 mmol, 1.5 equiv), Pd(PPh₃)₄ (57.8 mg, 0.50 mmol, 1.0 equiv), CuI (6.6 mg, 0.50 mmol, 1.0 equiv), CsF (224 mg, 1.18 mmol, 2.35 equiv), and DMF (10 mL, 0.1 M). The reaction mixture was subjected to the purification outlined in General Procedure C (silica gel, Et₂O:petroleum ether, 1:99) to afford the desired product as a white solid (42.0 mg, 40%).

 v_{max} (film): 1655, 1595, 1499, 1425, 1312, 1287, 1206, 1123, 989, 841, 758, 669 cm⁻¹.

¹**H NMR (400 MHz, CDCl₃):** δ 8.20 (d, J = 8.6 Hz, 1H), 7.82 (dd, J = 7.5, 1.3 Hz, 1H), 7.72 (ddd, J = 8.1, 6.8, 1.4 Hz, 2H), 7.43 (dd, J = 8.2, 7.4 Hz, 1H), 6.06 (dd, ³ J_{HF} = 48.5 Hz, ² J_{HH} = 2.9 Hz, 1H), 5.17 (dd, ³ J_{HF} = 16.0 Hz, ² J_{HH} = 2.9 Hz, 1H).

¹³C NMR (126 MHz, CDCl₃): δ 161.9 (d, ¹*J* = 250.7 Hz), 150.60 (d, ²*J* = 37.5 Hz), 144.1 (d, ⁴*J* = 4.5 Hz), 137.6, 133.9, 130.2, 129.2, 126.9, 126.7, 117.5 (d, ³*J* = 4.4 Hz), 94.7 (d, ²*J* = 17.6 Hz).

¹⁹F NMR (376 MHz, CDCl₃): δ –115.61.

HRMS (ESI): exact mass calculated for $[M+H]^+$ (C₁₁H₈ClFN) requires m/z 208.0324, found m/z 208.0320.

(R)-N-(2-Fluoro-2-(quinolin-2-yl)ethyl)aniline 7a



Prepared according to General Procedure A using 2-(1-fluorovinyl)quinoline (17.3 mg, 0.10 mmol, 1.0 equiv), aniline (27 μ L, 0.30 mmol, 3.0 equiv), (*S*)-TRIP catalyst (15.1 mg, 0.02 mmol, 20 mol%), and THF (200 μ L, 0.5 M). The reaction mixture was subjected to the purification outlined in General Procedure A (silica gel, EtOAc:petroleum ether, 5:95 to 10:90) to afford the desired product as a pale yellow solid (21.8 mg, 82%).

 v_{max} (film): 3406 (br), 3051, 3019, 2926, 2846, 1600, 1504, 1061, 751 cm⁻¹.

¹**H NMR (500 MHz, CDCl₃):** δ 8.24 (d, J = 8.5 Hz, 1H), 8.11 (d, J = 8.5 Hz, 1H), 7.85 (d, J = 8.2 Hz, 1H), 7.79 – 7.71 (m, 1H), 7.64 (dd, J = 8.5, 1.2 Hz, 1H), 7.60 – 7.54 (m, 1H), 7.23 – 7.15 (m, 2H), 6.79 – 6.70 (m, 3H), 5.91 (ddd, ² J_{HF} = 48.7 Hz, J = 7.3, 3.7 Hz, 1H), 3.95 (ddd, ³ J_{HF} = 26.3 Hz, ² J_{HH} = 14.0 Hz, J = 3.8 Hz, 1H), 3.73 (ddd, ³ J_{HF} = 19.7 Hz, ² J_{HH} = 14.0 Hz, J = 7.3 Hz, 1H).

¹³C NMR (126 MHz, CDCl₃): δ 158.1 (d, ${}^{2}J$ = 24.5 Hz), 147.6, 147.5, 137.3, 130.1, 129.5, 129.3, 127.9, 127.9, 127.0, 118.2, 117.9 (d, ${}^{3}J$ = 6.7 Hz), 113.5, 93.4 (d, ${}^{1}J$ = 174.8 Hz), 48.6 (d, ${}^{2}J$ = 22.5 Hz).

¹⁹F NMR (**376** MHz, CDCl₃): δ –191.33.

HRMS (NSI): exact mass calculated for $[M+H]^+$ (C₁₇H₁₆N₂F) requires *m/z* 267.1292, found *m/z* 267.1293.

The enantiomeric purity of the product was determined by HPLC analysis: 96:4 e.r. (Chiralpak IA, hexane/*i*-PrOH = 90/10, flow rate 0.5 mL/min, λ = 250 nm), t_r (major) = 23.1 min, t_r (minor) = 25.2 min;



(R)-N-(2-Fluoro-2-(quinolin-2-yl)ethyl)-4-(methylthio)aniline 7b



Prepared according to General Procedure B using 2-(1-fluorovinyl)quinoline (17.3 mg, 0.10 mmol, 1.0 equiv), 4-(methylthio)aniline (41.7 mg, 0.30 mmol, 3.0 equiv), (*S*)-TRIP catalyst (15.1 mg, 0.02 mmol, 20 mol%), and CPME (200 μ L, 0.5 M). The reaction mixture was subjected to the purification outlined in General Procedure B (silica gel, EtOAc:petroleum ether, 5:95 to 10:90) to afford the desired product as a pale brown oil (29.0 mg, 93%).

 v_{max} (film): 3318 (br), 2970, 2916, 2839, 1597, 1504, 1319, 1034, 826 cm⁻¹.

¹**H NMR (500 MHz, CDCl₃):** δ 8.22 (d, J = 8.5 Hz, 1H), 8.10 (d, J = 8.5 Hz, 1H), 7.84 (d, J = 8.1 Hz, 1H), 7.79 – 7.72 (m, 1H), 7.63 (dd, J = 8.5, 1.2 Hz, 1H), 7.57 (t, J = 7.5 Hz, 1H), 7.21 (d, J = 8.6 Hz, 2H), 6.66 (d, J = 8.6 Hz, 2H), 5.89 (ddd, ² J_{HF} = 48.6 Hz, J = 7.3, 3.7 Hz, 1H), 4.29 (s, 1H), 3.92 (ddd, ³ J_{HF} = 26.1 Hz, ² J_{HH} = 14.1 Hz, J = 3.5 Hz, 1H), 3.71 (ddd, ³ J_{HF} = 21.0 Hz, ² J_{HH} = 14.1 Hz, J = 7.3 Hz, 1H), 2.40 (s, 3H).

¹³C NMR (126 MHz, CDCl₃): δ 158.1, 157.9, 146.5, 137.3, 131.4, 130.1, 129.2, 127.9, 127.0, 125.8, 125.2, 117.9 (d, ³*J* = 6.4 Hz), 114.1, 93.3 (d, ¹*J* = 174.9 Hz), 48.6 (d, ²*J* = 22.4 Hz), 19.1.

¹⁹F NMR (470 MHz, CDCl₃): δ –191.43.

HRMS (NSI): exact mass calculated for $[M+H]^+$ (C₁₈H₁₈N₂FS) requires *m/z* 313.1169, found *m/z* 313.1165.

The enantiomeric purity of the product was determined by HPLC analysis: 97:3 e.r. (Chiralpak IA, hexane/*i*-PrOH = 90/10, flow rate 0.5 mL/min, λ = 250 nm), t_r (major) = 25.2 min, t_r (minor) = 27.1 min;

 $[\alpha]_{\rm D}^{20} = +4.4 \ (c \ 1.45, \rm CHCl_3).$



(R)-N-(2-Fluoro-2-(quinolin-2-yl)ethyl)-2,3-dihydro-1H-inden-5-amine 7c



Prepared according to General Procedure B using 2-(1-fluorovinyl)quinoline (17.3 mg, 0.10 mmol, 1.0 equiv), 2,3-dihydro-1*H*-inden-5-amine (39.9 mg, 0.30 mmol, 3.0 equiv), (*S*)-TRIP catalyst (15.1 mg, szr

0.02 mmol, 20 mol%), and CPME (200 μ L, 0.5 M). The reaction mixture was subjected to the purification outlined in General Procedure B (silica gel, EtOAc:petroleum ether, 5:95 to 10:90) to afford the desired product as a pale yellow oil (27.2 mg, 89%).

 v_{max} (film): 3395 (br), 3041, 3006, 2930, 2839, 1599, 1502, 1058, 833 cm⁻¹.

¹**H** NMR (500 MHz, CDCl₃): δ 8.22 (d, J = 8.5 Hz, 1H), 8.10 (d, J = 8.7 Hz, 1H), 7.84 (d, J = 8.1 Hz, 1H), 7.75 (ddd, J = 8.4, 6.9, 1.5 Hz, 1H), 7.63 (dd, J = 8.5, 1.5 Hz, 1H), 7.57 (ddd, J = 8.1, 6.9, 1.2 Hz, 1H), 7.04 (d, J = 8.0 Hz, 1H), 6.67 – 6.61 (m, 1H), 6.54 (dd, J = 8.0, 2.3 Hz, 1H), 5.90 (ddd, ² J_{HF} = 48.8 Hz, J = 7.4, 3.7 Hz, 1H), 4.13 (s, 1H), 3.92 (ddd, ³ J_{HF} = 26.4 Hz, ² J_{HH} =14.0 Hz, J = 3.7 Hz, 1H), 3.70 (ddd, ³ J_{HF} = 19.6 Hz, ² J_{HH} = 14.0 Hz, J = 7.4 Hz, 1H), 2.86 – 2.75 (m, 4H), 2.12 – 1.90 (m, 2H).

¹³C NMR (126 MHz, CDCl₃): δ 158.3 (d, ²*J* = 24.5 Hz), 147.5, 146.4, 145.6, 137.2, 134.0, 130.0, 129.4, 127.8, 126.9, 124.9, 118.0, 117.9, 112.0, 109.8, 93.4 (d, ¹*J* = 174.4 Hz), 49.2 (d, ²*J* = 22.4 Hz), 33.2, 32.1, 25.8.

¹⁹F NMR (376 MHz, CDCl₃): δ –191.30.

HRMS (NSI): exact mass calculated for $[M+H]^+$ (C₂₀H₂₀N₂F) requires m/z 307.1605, found m/z 307.1607.

The enantiomeric purity of the product was determined by HPLC analysis: 91:9 e.r. (Chiralcel OJ-H, hexane/*i*-PrOH = 50/50, flow rate 1.0 mL/min, $\lambda = 210$ nm), t_r (major) = 25.7 min, t_r (minor) = 38.8 min;

Area Percent Report Sorted By Signal Multiplier 1.0000 1.0000 Dilution Use Multiplier & Dilution Factor with ISTDs Signal 1: VWD1 A, Wavelength=250 nm Peak RetTime Type Width Area Height Area [min] [min] [mAU*s] [mAU] 25.297 BB 0.7026 2218.92896 49.04015 50.0879 37.771 BB 49,9121 31,50676

 $[\alpha]_{\rm D}^{20} = +7.0 \ (c \ 1.36, \rm CHCl_3).$



(R)-3-Bromo-N-(2-fluoro-2-(quinolin-2-yl)ethyl)aniline 7d



Prepared according to General Procedure B using 2-(1-fluorovinyl)quinoline (17.3 mg, 0.10 mmol, 1.0 equiv), 3-bromoaniline (53.1 mg, 0.30 mmol, 3.0 equiv), (*S*)-TRIP catalyst (15.1 mg, 0.02 mmol, 20 mol%), and CPME (200 μ L, 0.5 M). The reaction mixture was subjected to the purification outlined in General Procedure B (silica gel, EtOAc:petroleum ether, 5:95 to 10:90) to afford the desired product as a pale yellow oil (30.3 mg, 88%).

 v_{max} (film): 3418 (br), 3063, 2924, 2847, 1589, 1504, 1065, 833, 764 cm⁻¹.

¹**H NMR (400 MHz, CDCl₃):** δ 8.23 (d, J = 8.5 Hz, 1H), 8.11 (d, J = 8.5 Hz, 1H), 7.85 (d, J = 8.2 Hz, 1H), 7.76 (ddd, J = 8.4, 6.9, 1.4 Hz, 1H), 7.63 (dd, J = 8.5, 1.3 Hz, 1H), 7.58 (ddd, J = 8.0, 7.0, 1.0 Hz, 1H), 7.01 (t, J = 8.0 Hz, 1H), 6.87 – 6.79 (m, 2H), 6.65 – 6.57 (m, 1H), 5.89 (ddd, ² J_{HF} = 48.5 Hz, J = 7.0, 3.8 Hz, 1H), 4.33 (s, 1H), 3.91 (ddd, ³ J_{HF} = 25.0 Hz, ² J_{HH} = 14.1 Hz, J = 3.8 Hz, 1H), 3.73 (ddd, ³ J_{HF} = 20.8 Hz, ² J_{HH} = 14.1 Hz, J = 7.0 Hz, 1H).

¹³C NMR (126 MHz, CDCl₃): δ 157.7 (d, ²*J* = 24.6 Hz), 149.0, 147.4 (d, ⁴*J* = 2.3 Hz), 137.4, 130.6, 130.2, 129.2, 127.9, 127.8, 127.0, 123.4, 120.8, 117.8 (d, ³*J* = 6.5 Hz), 115.9, 112.0, 93.2 (d, ¹*J* = 175.2 Hz), 48.2 (d, ²*J* = 22.4 Hz).

¹⁹F NMR (**377** MHz, CDCl₃): δ –191.34.

HRMS (ESI): exact mass calculated for $[M+H]^+$ (C₁₇H₁₅N₂BrF) requires *m/z* 345.0397, found *m/z* 345.0395.

The enantiomeric purity of the product was determined by HPLC analysis: 94:6 e.r. (Chiralpak IA, hexane/*i*-PrOH = 90/10, flow rate 0.5 mL/min, $\lambda = 250$ nm), t_r (major) = 16.7 min, t_r (minor) = 17.5 min;



 $[\alpha]_{D}^{20} = +31.4 \ (c \ 2.12, \ CHCl_{3}).$

(R)-N-(2-Fluoro-2-(quinolin-2-yl)ethyl)-4-(trifluoromethyl)aniline 7e



Prepared according to General Procedure B using 2-(1-fluorovinyl)quinoline (17.3 mg, 0.10 mmol, 1.0 equiv), 4-(trifluoromethyl)aniline (48.3 mg, 0.30 mmol, 3.0 equiv), (S)-TRIP catalyst (15.1 mg, 0.02 mmol, 20 mol%), and CPME (200 μ L, 0.5 M). The reaction mixture was subjected to the purification outlined in General Procedure B (silica gel, EtOAc:petroleum ether, 5:95 to 10:90) to afford the desired product as a pale yellow oil (31.2 mg, 93%).

 v_{max} (film): 3426 (br), 3055, 2963, 2839, 1612, 1535, 1319, 1103, 1065, 826 cm⁻¹.

¹**H** NMR (500 MHz, CDCl₃): δ 8.24 (d, J = 8.5 Hz, 1H), 8.11 (d, J = 8.5 Hz, 1H), 7.85 (dd, J = 8.1, 1.4 Hz, 1H), 7.77 (ddd, J = 8.4, 6.8, 1.4 Hz, 1H), 7.64 (dd, J = 8.5, 1.6 Hz, 1H), 7.59 (ddd, J = 8.2, 6.9, 1.2 Hz, 1H), 7.40 (d, J = 8.5 Hz, 2H), 6.71 (d, J = 8.5 Hz, 2H), 5.90 (ddd, ² J_{HF} = 48.5 Hz, J = 7.0, 3.8 Hz, 1H), 4.61 (s, 1H), 3.99 (ddd, ³ J_{HF} = 25.1 Hz, ² J_{HH} = 14.2 Hz, J = 3.8 Hz, 1H), 3.80 (ddd, ³ J_{HF} = 20.9 Hz, ² J_{HH} = 14.2 Hz, J = 7.0 Hz, 1H).

¹³C NMR (126 MHz, CDCl₃): δ 157.6 (d, ²*J* = 24.8 Hz), 150.2, 147.4, 137.5, 130.3, 129.2, 127.9, 127.9, 127.1, 126.8 (q, ³*J* = 3.8 Hz), 125.0 (q, ¹*J* = 270.4 Hz), 119.6 (q, ²*J* = 32.6 Hz), 117.8 (d, ³*J* = 6.7 Hz), 112.5, 93.1 (d, ¹*J* = 175.6 Hz), 47.9 (d, ²*J* = 22.4 Hz).

¹⁹F NMR (470 MHz, CDCl₃): δ -61.07, -191.49.

HRMS (NSI): exact mass calculated for $[M+H]^+$ (C₁₈H₁₅N₂F₄) requires m/z 335.1166, found m/z 336.1158.

The enantiomeric purity of the product was determined by HPLC analysis: 97:3 e.r. (Chiralpak IA, hexane/*i*-PrOH = 90/10, flow rate 0.5 mL/min, λ = 250 nm), tr (major) = 17.2 min, tr (minor) = 18.2 min;

 $[\alpha]_{D}^{20} = +4.7 \ (c \ 1.07, \text{CHCl}_3).$



Sorted By	:	Signal	
Multiplier	:	1.0000	
Dilution	:	1.0000	
Jse Multiplier	Dilution	Factor with	ISTDs

Signal 1: VWD1 A, Wavelength=250 nm

?eak	RetTime	Type	Width	Area	Height	Area
+	[min]		[min]	[mAU*s]	[mAU]	8
1	17.551	BV	0.3124	5980.82959	292.94598	49.6500
2	18.697	VB	0.3454	6065.15576	268.12650	50.3500



(R)-N-(2-Fluoro-2-(quinolin-2-yl)ethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline 7f



Prepared according to General Procedure A using 2-(1-fluorovinyl)quinoline (17.3 mg, 0.10 mmol, 1.0 equiv), 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (65.7 mg, 0.30 mmol, 3.0 equiv), (*S*)-TRIP catalyst (15.1 mg, 0.02 mmol, 20 mol%), and THF (200 μ L, 0.5 M) at -20 °C for 5 d. The reaction mixture was subjected to the purification outlined in General Procedure A (silica gel, EtOAc:petroleum ether, 5:95 to 10:90) to afford the desired product as a pale yellow solid (31.0 mg, 79%).

 v_{max} (film): 3401 (br), 3041, 2973, 2928, 1606, 1359, 1145 cm⁻¹.

¹**H** NMR (400 MHz, CD₂Cl₂): δ 8.27 (d, J = 8.5 Hz, 1H), 8.09 (d, J = 8.5 Hz, 1H), 7.88 (d, J = 8.2 Hz, 1H), 7.76 (ddd, J = 8.4, 6.9, 1.4 Hz, 1H), 7.63 (dd, J = 8.5, 1.4 Hz, 1H), 7.61 – 7.50 (m, 3H), 6.75 – 6.63 (m, 2H), 5.87 (ddd, ² J_{HF} = 48.6 Hz, J = 7.1, 3.8 Hz, 1H), 4.52 (s, 1H), 3.97 (m, 1H), 3.79 (ddd, ³ J_{HF} = 20.1 Hz, ² J_{HH} = 13.4 Hz, J = 6.3 Hz, 1H), 1.30 (s, 12H).

¹³C NMR (101 MHz, CD₂Cl₂): δ 158.2 (d, ²*J* = 24.4 Hz), 150.6, 137.5, 136.6, 136.6, 130.3, 129.5, 128.2, 128.1, 128.1, 127.2, 118.2 (d, ³*J* = 6.1 Hz), 112.5, 93.7 (d, ¹*J* = 174.8 Hz), 83.6, 48.0 (d, ²*J* = 22.4 Hz), 25.1.

¹⁹F NMR (376 MHz, CD₂Cl₂): δ –190.85.

¹¹B NMR (128 MHz, CD₂Cl₂): δ 30.69.

HRMS (NSI): exact mass calculated for $[M+H]^+$ (C₂₃H₂₇N₂O₂FB) requires *m/z* 392.2154, found *m/z* 393.2202.

The enantiomeric purity of the product was determined by HPLC analysis: 93:7 e.r. (Chiralpak IA, hexane/*i*-PrOH = 90/10, flow rate 0.5 mL/min, $\lambda = 250$ nm), t_r (major) = 17.5 min, t_r (minor) = 18.9 min;



 $[\alpha]_{\rm D}^{20} = +43.4 \ (c \ 0.15, \ {\rm CHCl}_3).$



(R)-4-Bromo-N-(2-fluoro-2-(quinolin-2-yl)ethyl)aniline 7g



Prepared according to General Procedure A using 2-(1-fluorovinyl)quinoline (17.3 mg, 0.10 mmol, 1.0 equiv), 4-bromoaniline (51.6 mg, 0.30 mmol, 3.0 equiv), (S)-TRIP catalyst (15.1 mg, 0.02 mmol, 20 mol%), and THF (200 μ L, 0.5 M) at -20 °C for 5 d. The reaction mixture was subjected to the purification outlined in General Procedure A (silica gel, EtOAc:petroleum ether, 5:95 to 10:90) to afford the desired product as a pale yellow oil (24.4 mg, 71%).

 v_{max} (film): 3403 (br), 3026, 2928, 2851, 1599, 813 cm⁻¹.

¹**H NMR (400 MHz, CDCl₃):** δ 8.23 (d, J = 8.5 Hz, 1H), 8.09 (d, J = 8.4 Hz, 1H), 7.85 (d, J = 8.1 Hz, 1H), 7.76 (ddd, J = 8.4, 6.9, 1.4 Hz, 1H), 7.63 (dd, J = 8.5, 1.5 Hz, 1H), 7.58 (ddd, J = 8.1, 6.9, 1.1 Hz, 1H), 7.26 – 7.22 (m, 1H), 6.62 – 6.56 (m, 2H), 5.87 (ddd, ² J_{HF} = 48.7 Hz, J = 7.1, 3.8 Hz, 2H), 4.28 (t, J = 5.8 Hz, 1H), 3.91 (dddd, ³ J_{HF} = 25.4 Hz, ² J_{HH} = 14.0 Hz, J = 7.3, 3.8 Hz, 1H), 3.78 – 3.65 (m, 1H).

¹³C NMR (101 MHz, CDCl₃): δ 157.9 (d, ²*J* = 24.5 Hz), 146.7, 137.3, 132.2, 132.1, 130.2, 129.4, 127.9, 127.0, 117.9 (d, ³*J* = 6.9 Hz), 115.0, 109.8, 94.1, 93.3 (d, ¹*J* = 175.0 Hz), 48.5 (d, ²*J* = 22.4 Hz).

¹⁹F NMR (376 MHz, CDCl₃): δ –191.44.

HRMS (NSI): exact mass calculated for $[M+H]^+$ (C₁₇H₁₅N₂FBr) requires *m/z* 345.0403, found *m/z* 345.0400.

The enantiomeric purity of the product was determined by HPLC analysis: 90:10 e.r. (Chiralpak IA, hexane/*i*-PrOH = 50/50, flow rate 0.3 mL/min, $\lambda = 250$ nm), t_r (major) = 14.1 min, t_r (minor) = 15.0 min;





(R)-2-Fluoro-N-(2-fluoro-2-(quinolin-2-yl)ethyl)aniline 7h



Prepared according to General Procedure B using 2-(1-fluorovinyl)quinoline (17.3 mg, 0.10 mmol, 1.0 equiv), 2-fluoroaniline (33.3 mg, 0.30 mmol, 3.0 equiv), (*S*)-TRIP catalyst (15.1 mg, 0.02 mmol, 20 mol%), and CPME (200 μ L, 0.5 M). The reaction mixture was subjected to the purification outlined in General Procedure B (silica gel, EtOAc:petroleum ether, 5:95 to 10:90) to afford the desired product as a pale yellow oil (13.1 mg, 46%).

 v_{max} (film): 3422 (br), 3065, 2928, 2857, 1620, 1516, 1506, 1190, 829, 743 cm⁻¹.

¹**H NMR (400 MHz, CDCl₃):** δ 8.24 (d, J = 8.5 Hz, 1H), 8.10 (d, J = 8.8 Hz, 1H), 7.85 (d, J = 7.2 Hz, 1H), 7.76 (ddd, J = 8.4, 6.9, 1.4 Hz, 1H), 7.65 (dd, J = 8.5, 1.6 Hz, 1H), 7.57 (ddd, J = 8.1, 6.9, 1.1 Hz, 1H), 7.04 – 6.91 (m, 2H), 6.84 (td, J = 8.5, 1.4 Hz, 1H), 6.69 – 6.55 (m, 1H), 5.91 (ddd, ² J_{HF} = 48.6 Hz, J = 7.1, 3.8 Hz, 1H), 4.56 (s, 1H), 3.97 (dddd, ³ J_{HF} = 25.3 Hz, ² J_{HH} = 14.1 Hz, J = 7.1, 3.7 Hz, 1H), 3.84 – 3.71 (m, 1H).

¹³C NMR (101 MHz, CDCl₃): δ 158.0 (d, ²*J* = 24.6 Hz), 151.9 (d, ¹*J* = 238.8 Hz), 147.6 (d, ⁴*J* = 1.8 Hz), 137.3, 136.2 (d, ³*J* = 11.0 Hz), 130.1, 129.4, 127.9, 127.0, 124.7, 124.7, 117.9 (d, ³*J* = 6.9 Hz), 117.4 (d, ³*J* = 7.1 Hz), 114.7 (d, ²*J* = 18.7 Hz), 112.7 (d, ⁴*J* = 2.7 Hz), 93.3 (d, ¹*J* = 175.4 Hz), 48.2 (d, ²*J* = 22.4 Hz).

¹⁹F NMR (376 MHz, CDCl₃): δ –136.12, –191.53.

HRMS (NSI): exact mass calculated for $[M+H]^+$ (C₁₇H₁₅N₂F₂) requires *m/z* 285.1203, found *m/z* 285.1202.

The enantiomeric purity of the product was determined by HPLC analysis: 89:11 e.r. (Chiralcel OJ-H, hexane/*i*-PrOH = 50/50, flow rate 0.5 mL/min, λ = 250 nm), t_r (major) = 19.7 min, t_r (minor) = 22.0 min;

 $[\alpha]_{D}^{20} = +3.4 \ (c \ 0.65, \text{CHCl}_3).$


(R)-3-Fluoro-N-(2-fluoro-2-(quinolin-2-yl)ethyl)-4-methylaniline 7i



Prepared according to General Procedure B using 2-(1-fluorovinyl)quinoline (17.3 mg, 0.10 mmol, 1.0 equiv), 3-fluoro-4-methylaniline (37.5 mg, 0.30 mmol, 3.0 equiv), (S)-TRIP catalyst (15.1 mg, 0.02

mmol, 20 mol%), and CPME (200 μ L, 0.5 M). The reaction mixture was subjected to the purification outlined in General Procedure B (silica gel, EtOAc:petroleum ether, 5:95 to 10:90) to afford the desired product as a pale yellow oil (29.2 mg, 98%).

 v_{max} (film): 3433 (br), 3048, 2924, 2862, 1636, 1597, 1520, 833 cm⁻¹.

¹**H** NMR (500 MHz, CDCl₃): δ 8.23 (d, J = 8.5 Hz, 1H), 8.09 (d, J = 8.5 Hz, 1H), 7.84 (d, J = 8.1 Hz, 1H), 7.78 – 7.71 (m, 1H), 7.66 – 7.60 (m, 1H), 7.57 (t, J = 7.4 Hz, 1H), 6.82 (t, J = 9.1 Hz, 1H), 6.52 (dd, J = 13.3, 2.7 Hz, 1H), 6.41 (dd, J = 8.7, 1.2 Hz, 1H), 5.87 (ddd, ²J_{HF} = 48.7 Hz, J = 7.2, 3.7 Hz, 1H), 4.12 (s, 1H), 3.94 – 3.82 (m, 1H), 3.74 – 3.62 (m, 1H), 2.15 (s, 3H).

¹³C NMR (126 MHz, CDCl₃): δ 162.2 (d, ¹*J* = 242.4 Hz), 157.9 (d, ²*J* = 24.6 Hz), 147.4, 147.3 (d, ³*J* = 10.6 Hz), 137.3, 131.8 (d, ³*J* = 7.1 Hz), 130.1, 129.3, 127.9, 127.8, 127.0, 117.8 (d, ³*J* = 6.5 Hz), 113.6 (d, ²*J* = 17.7 Hz), 109.15 (d, ⁴*J* = 2.4 Hz), 100.4 (d, ²*J* = 26.1 Hz), 93.2 (d, ¹*J* = 174.8 Hz), 48.7 (d, ²*J* = 22.4 Hz), 13.7 (d, ⁴*J* = 3.3 Hz).

¹⁹F NMR (470 MHz, CDCl₃): δ –116.69, –191.35.

HRMS (ESI): exact mass calculated for $[M+H]^+$ (C₁₈H₁₇ON₂F₂) requires *m/z* 299.1354, found *m/z* 299.1351.

The enantiomeric purity of the product was determined by HPLC analysis: 98:2 e.r. (Chiralpak IA, hexane/*i*-PrOH = 90/10, flow rate 0.3 mL/min, $\lambda = 250$ nm), t_r (major) = 16.3 min, t_r (minor) = 17.1 min;

 $[\alpha]_{\rm D}^{20} = +14.6 \ (c \ 1.6, \ {\rm CHCl}_3).$





(R)-3-Fluoro-N-(2-fluoro-2-(quinolin-2-yl)ethyl)-4-methoxyaniline 7j



Prepared according to General Procedure A using 2-(1-fluorovinyl)quinoline (17.3 mg, 0.10 mmol, 1.0 equiv), 3-fluoro-4-methoxyaniline (42.3 mg, 0.30 mmol, 3.0 equiv), (S)-TRIP catalyst (15.1 mg, 0.02 mmol, 20 mol%), and THF (200 μ L, 0.5 M). The reaction mixture was subjected to the purification outlined in General Procedure A (silica gel, EtOAc:petroleum ether, 5:95 to 10:90) to afford the desired product as a pale yellow oil (24.6 mg, 72%).

 v_{max} (film): 3398 (br), 3056, 2948, 2932, 2833, 1519, 1227 cm⁻¹.

¹**H NMR (500 MHz, CDCl₃):** δ 8.23 (d, J = 8.5 Hz, 1H), 8.09 (d, J = 8.5 Hz, 1H), 7.84 (d, J = 8.1 Hz, 1H), 7.78 – 7.71 (m, 1H), 7.66 – 7.60 (m, 1H), 7.57 (t, J = 7.4 Hz, 1H), 6.82 (t, J = 9.1 Hz, 1H), 6.52 (dd, J = 13.3, 2.7 Hz, 1H), 6.41 (dd, J = 8.7, 1.2 Hz, 1H), 5.87 (ddd, ²J_{HF} = 48.7 Hz, J = 7.2, 3.7 Hz, 1H), 4.12 (s, 1H), 3.94 – 3.82 (m, 1H), 3.80 (s, 3H), 3.74 – 3.62 (m, 1H).

¹³C NMR (126 MHz, CDCl₃): δ 158.0 (d, ²*J* = 24.6 Hz), 153.7 (d, ¹*J* = 244.2 Hz), 147.5, 142.8 (d, ³*J* = 9.1 Hz), 140.0 (d, ³*J* = 11.3 Hz), 137.3, 130.1, 129.4, 127.9, 127.9, 127.0, 117.8 (d, ³*J* = 6.5 Hz), 116.1 (d, ⁴*J* = 3.1 Hz), 108.7 (d, ⁴*J* = 3.2 Hz), 102.7 (d, ²*J* = 22.0 Hz), 93.3 (d, ¹*J* = 174.7 Hz), 57.7, 49.3 (d, ²*J* = 22.5 Hz).

¹⁹F NMR (376 MHz, CDCl₃): δ –133.38, –191.48.

HRMS (NSI): exact mass calculated for $[M+H]^+$ (C₁₈H₁₇ON₂F₂) requires *m/z* 315.1303, found *m/z* 315.1306.

The enantiomeric purity of the product was determined by HPLC analysis: 93:7 e.r. (Chiralcel OJ-H, hexane/*i*-PrOH = 70/30, flow rate 0.5 mL/min, $\lambda = 250$ nm), t_r (major) = 92.3 min, t_r (minor) = 97.7 min;



 $[\alpha]_{D}^{20} = +7.9 \ (c \ 1.2, \ CHCl_3).$

eak	RetTime	Type	Width	Area	Height	Area
+	[min]		[min]	[mAU*s]	[mAU]	융
1	92.314	MM	2.0188	2.54037e4	209.72574	93.2525
2	97.707	MM	1.7613	1838.15466	17.39389	6.7475

(R)-N-(2-Fluoro-2-(quinolin-2-yl)ethyl)benzo[b]thiophen-5-amine 7k



Prepared according to General Procedure A using 2-(1-fluorovinyl)quinoline (17.3 mg, 0.10 mmol, 1.0 equiv), benzo[*b*]thiophen-5-amine (44.7 mg, 0.30 mmol, 3.0 equiv), (*S*)-TRIP catalyst (15.1 mg, 0.02 mmol, 20 mol%), and THF (200 μ L, 0.5 M) at -20 °C for 5 d. The reaction mixture was subjected to the purification outlined in General Procedure A (silica gel, EtOAc:petroleum ether, 5:95 to 10:90) to afford the desired product as a pale yellow solid (18.7 mg, 58%).

 v_{max} (film): 3389 (br), 3058, 3021, 2924, 2848, 1599, 1504, 1437, 1065, 831, 749, 691 cm⁻¹.

¹**H NMR (500 MHz, MeOD):** δ 8.30 (d, J = 8.5 Hz, 1H), 8.07 (d, J = 8.5 Hz, 1H), 7.88 (d, J = 8.1 Hz, 1H), 7.82 – 7.73 (m, 1H), 7.65 (d, J = 8.4 Hz, 1H), 7.57 (t, J = 7.2 Hz, 1H), 7.54 (d, J = 8.7 Hz, 1H), 7.36 (d, J = 5.4 Hz, 1H), 7.08 (d, J = 5.7 Hz, 2H), 6.81 (dd, J = 8.7, 2.2 Hz, 1H), 5.86 (ddd, ² J_{HF} = 48.7 Hz, J = 7.5, 3.4 Hz, 1H), 3.86 (ddd, ³ J_{HF} = 27.5 Hz, ² J_{HH} = 14.6 Hz, J = 3.4 Hz, 1H), 3.71 (ddd, ³ J_{HF} = 20.2 Hz, ² J_{HH} = 14.6 Hz, J = 7.5 Hz, 1H). (N-H proton not observed)

¹³C NMR (126 MHz, MeOD): δ 159.7 (d, ²*J* = 23.9 Hz), 148.4, 146.9, 142.4, 138.9, 131.3, 130.7, 129.3, 129.3, 129.1, 128.1, 127.5, 124.4, 123.5, 119.3 (d, ³*J* = 6.0 Hz), 115.3, 106.2, 94.4 (d, ¹*J* = 174.9 Hz), 50.1 (d, ²*J* = 23.2 Hz).

¹⁹F NMR (376 MHz, MeOD): δ –190.65.

HRMS (NSI): exact mass calculated for $[M+H]^+$ (C₁₉H₁₆N₂FS) requires *m/z* 323.1013, found *m/z* 323.1016.

The enantiomeric purity of the product was determined by HPLC analysis: 94:6 e.r. (Chiralpak IA, hexane/*i*-PrOH = 50/50, flow rate 0.5 mL/min, λ = 250 nm), t_r (major) = 14.9 min, t_r (minor) = 15.8 min;

 $[\alpha]_{D}^{20} = +9.0 \ (c \ 0.94, \text{CHCl}_3).$



Area Percent Report

Sorted By	:	Signal	
dultiplion.		1 0000	

4u ± 1	ciplier			1.00	000	
Dilu	ution		:	1.00	000	
Jse	Multiplier	&	Dilution	Factor	with	ISTDs

Signal 1: VWD1 A, Wavelength=250 nm



(R)-N-(2-Fluoro-2-(quinolin-2-yl)ethyl)-2,3-dihydrobenzofuran-5-amine 71



Prepared according to General Procedure A using 2-(1-fluorovinyl)quinoline (17.3 mg, 0.10 mmol, 1.0 equiv), 2,3-dihydrobenzofuran-5-amine (40.5 mg, 0.30 mmol, 3.0 equiv), (*S*)-TRIP catalyst (15.1 mg, s42

0.02 mmol, 20 mol%), and THF (200 μ L, 0.5 M) at -20 °C for 5 d. The reaction mixture was subjected to the purification outlined in General Procedure A (silica gel, EtOAc:petroleum ether, 5:95 to 10:100) to afford the desired product as a pale yellow oil (11.4 mg, 37%).

 v_{max} (film): 3376 (br), 3051, 2954, 2921, 2887, 2850, 1491, 1216 cm⁻¹.

¹**H NMR (400 MHz, CDCl₃):** δ 8.22 (d, J = 8.5 Hz, 1H), 8.09 (dd, J = 8.6, 1.1 Hz, 1H), 7.84 (dd, J = 8.2, 1.4 Hz, 1H), 7.75 (ddd, J = 8.4, 6.8, 1.5 Hz, 1H), 7.63 (dd, J = 8.5, 1.5 Hz, 1H), 7.57 (ddd, J = 8.1, 6.8, 1.2 Hz, 1H), 6.70 – 6.62 (m, 2H), 6.51 (dd, J = 8.5, 2.5 Hz, 1H), 5.89 (ddd, ² J_{HF} = 48.7 Hz, J = 7.4, 3.7 Hz, 1H), 4.55 – 4.39 (m, 2H), 3.86 (ddd, ³ J_{HF} = 26.5 Hz, ² J_{HH} = 13.9 Hz, J = 3.7 Hz, 1H), 3.67 (ddd, ³ J_{HF} = 19.6 Hz, ² J_{HH} 13.9 Hz, J = 7.4 Hz, 1H), 3.19 – 3.01 (m, 2H).

¹³C NMR (101 MHz, CDCl₃): δ 158.3 (d, ²*J* = 24.8 Hz), 153.2, 147.5, 141.9, 137.2, 130.0, 129.3, 128.0, 127.8, 126.9, 118.0, 117.9, 113.6, 111.5, 109.5, 93.4 (d, ¹*J* = 174.2 Hz), 71.1, 50.2 (d, ²*J* = 22.2 Hz), 30.4.

¹⁹F NMR (376 MHz, CDCl₃): δ –191.64.

HRMS (NSI): exact mass calculated for $[M+H]^+$ (C₁₉H₁₈ON₂F) requires *m/z* 309.1398, found *m/z* 309.1401.

The enantiomeric purity of the product was determined by HPLC analysis: 89:11 e.r. (Chiralcel OJ-H, hexane/*i*-PrOH = 50/50, flow rate 0.5 mL/min, λ = 250 nm), t_r (major) = 55.0 min, t_r (minor) = 60.2 min;

mAL 57.377 30 72 25 20 15 10 60 70 Area Percent Report Sorted By Signal Aultiplier 1.0000 Dilution Jse Multiplier & Dilution Factor with ISTDs Signal 1: VWD1 A, Wavelength=250 nm Peak RetTime Type Width Area Height Area [mAU] [min] [mAU*s] [min] 57.377 BB 1.1785 2316.01807 30,10777 50.0123 61.772 BB 1.2849 2314.87866 27.54219 49.9877

 $[\alpha]_{\rm D}^{20} = +2.5 \ (c \ 0.57, \rm CHCl_3).$



(R)-2-(1-Fluoro-2-(indolin-1-yl)ethyl)quinoline 7m



Prepared according to General Procedure B using 2-(1-fluorovinyl)quinoline (17.3 mg, 0.10 mmol, 1.0 equiv), indoline (35.7 mg, 0.30 mmol, 3.0 equiv), (*S*)-TRIP catalyst (15.1 mg, 0.02 mmol, 20 mol%), and CPME (200 μ L, 0.5 M). The reaction mixture was subjected to the purification outlined in General Procedure B (silica gel, EtOAc:petroleum ether, 5:95 to 10:100) to afford the desired product as a pale yellow solid (26.9 mg, 92%).

 v_{max} (film): 3048, 3024, 2949, 2922, 2845, 1607, 1599, 1489, 1244, 742 cm⁻¹.

¹**H** NMR (400 MHz, CDCl₃): δ 8.22 (d, J = 8.5 Hz, 1H), 8.12 (d, J = 8.4 Hz, 1H), 7.84 (dd, J = 8.2, 0.9 Hz, 1H), 7.75 (ddd, J = 8.4, 6.9, 1.4 Hz, 1H), 7.67 (dd, J = 8.5, 1.4 Hz, 1H), 7.57 (ddd, J = 8.1, 6.9, 1.1 Hz, 1H), 7.09 – 7.00 (m, 2H), 6.65 (td, J = 7.4, 0.8 Hz, 1H), 6.56 (d, J = 7.8 Hz, 1H), 5.98 (ddd, ² $J_{\rm HF}$ = 48.7 Hz, J = 6.8, 2.9 Hz, 1H), 3.86 (ddd, ³ $J_{\rm HF}$ = 28.6 Hz, ² $J_{\rm HH}$ = 15.1 Hz, J = 2.9 Hz, 1H), 3.72 (ddd, ³ $J_{\rm HF}$ = 24.0 Hz, ² $J_{\rm HH}$ = 15.1 Hz, J = 6.8 Hz, 1H), 3.56 (q, J = 8.3 Hz, 1H), 3.48 (qd, J = 8.7, 0.8 Hz, 1H), 2.98 (t, J = 8.4 Hz, 2H).

¹³C NMR (101 MHz, CDCl₃): δ 158.5 (d, ²*J* = 24.8 Hz), 152.3, 147.6, 137.1, 130.0, 129.6, 129.4, 127.9, 127.8, 127.5, 126.8, 124.5, 118.1 (d, ³*J* = 6.2 Hz), 117.8, 106.9, 94.7 (d, ¹*J* = 176.7 Hz), 54.9, 54.8 (d, ²*J* = 20.9 Hz), 28.9.

¹⁹F NMR (**376** MHz, CDCl₃): δ –187.59.

HRMS (NSI): exact mass calculated for $[M+H]^+$ (C₁₉H₁₈N₂F) requires m/z 293.1449, found m/z 293.1450.

The enantiomeric purity of the product was determined by HPLC analysis: 92:8 e.r. (Chiralcel OJ-H, hexane/*i*-PrOH = 50/50, flow rate 0.5 mL/min, λ = 250 nm), t_r (major) = 24.9 min, t_r (minor) = 24.0 min;



ak	RetTime	Type	Width	Area	Height	Area
÷ .	[min]		[min]	[mAU*s]	[mAU]	8
1	24.003	MM	0.4411	5192.60156	196.21417	8.1506
2	24.894	MM	0.7268	5.85157e4	1341.82629	91.8494

(R)-N-(2-Fluoro-2-(3-methylquinolin-2-yl)ethyl)aniline 7n



Prepared according to General Procedure B using 3-methyl-2-(1-fluorovinyl)quinoline (18.8 mg. 0.10 mmol, 1.0 equiv), aniline (27 μ L, 0.30 mmol, 3.0 equiv), (S)-TRIP catalyst (15.1 mg, 0.02 mmol, 20 mol%), and CPME (200 μ L, 0.5 M) at -10 °C for 3 d. The reaction mixture was subjected to the purification outlined the General Procedure B (silica gel, EtOAc:petroleum ether, 5:95 to 1:100) to afford the desired product as a pale yellow solid (13.8 mg, 50%).

 v_{max} (film): 1603, 1506, 1497, 1447, 1325, 1261, 750, 692 cm⁻¹.

¹**H NMR (500 MHz, CDCl₃):** δ 8.12 (d, J = 8.4 Hz, 1H), 7.96 (s, 1H), 7.76 (d, J = 8.1 Hz, 1H), 7.69 (t, J = 7.6 Hz, 1H), 7.55 (t, J = 7.5 Hz, 1H), 7.21 (t, J = 7.8 Hz, 2H), 6.74 (dd, J = 10.9, 7.9 Hz, 3H), 6.00 (ddd, ²J_{HF} = 48.1 Hz, J = 7.2, 4.9 Hz, 1H), 4.41 (s, 1H), 4.12 – 3.91 (m, 2H), 2.58 (s, 3H).

¹³C NMR (126 MHz, CDCl₃): δ 155.2 (d, ³*J* = 18.1 Hz), 147.7, 146.0, 137.3, 129.9, 129.5, 129.4, 129.0, 128.2, 127.2, 126.8, 117.9, 113.2, 90.2 (d, ¹*J* = 172.8 Hz), 46.2 (d, ²*J* = 24.6 Hz), 18.6 (d, ⁴*J* = 3.3 Hz).

¹⁹F NMR (376 MHz, CDCl₃): δ –183.72.

HRMS (ESI): exact mass calculated for $[M+H]^+$ (C₁₈H₁₈FN₂) requires m/z 281.1449, found m/z 281.1441.

The enantiomeric purity of the product was determined by HPLC analysis: 91:9 e.r. (Chiralcel OJ-H, hexane/*i*-PrOH = 50/50, flow rate 1.0 mL/min, $\lambda = 250$ nm), t_r (major) = 28.8 min, t_r (minor) = 45.1 min;

 $[\alpha]_{D}^{20} = -71.9 \ (c \ 0.21, \ in \ CHCl_3).$



(R)-N-(2-Fluoro-2-(6-fluoroquinolin-2-yl)ethyl)aniline 70



Prepared according to General Procedure B using 6-fluoro-2-(1-fluorovinyl)quinoline (19.1 mg, 0.10 mmol, 1.0 equiv), aniline (27 µL, 0.30 mmol, 3.0 equiv), (S)-TRIP catalyst (15.1 mg, 0.02 mmol, 20 s47

mol%), and CPME (200 μ L, 0.5 M) at -10 °C for 3 d. The reaction mixture was subjected to the purification outlined in General Procedure B (silica gel, EtOAc:petroleum ether, 5:95 to 10:100) to afford the desired product as a pale brown oil (18.9 mg, 67%).

 v_{max} (film): 1603, 1506, 1323, 1260, 1231, 1142, 1061, 872, 833, 750, 692 cm⁻¹.

¹**H NMR (400 MHz, CDCl₃):** δ 8.17 (d, J = 8.6 Hz, 1H), 8.10 (dd, J = 9.2, 5.3 Hz, 1H), 7.65 (d, J = 8.5 Hz, 1H), 7.52 (td, J = 8.7, 2.8 Hz, 1H), 7.46 (dd, J = 8.8, 2.8 Hz, 1H), 7.19 (t, J = 7.8 Hz, 2H), 6.78 – 6.70 (m, 3H), 5.88 (ddd, ² J_{HF} = 48.6 Hz, J = 7.3, 3.6 Hz, 1H), 3.94 (ddd, ³ J_{HF} = 26.4 Hz, ² J_{HH} = 14.1 Hz, J = 3.7 Hz, 1H), 3.72 (ddd, ³ J_{HF} = 20.0 Hz, ² J_{HH} = 14.1 Hz, J = 7.3 Hz, 1H).

¹³C NMR (101 MHz, CDCl₃): δ 160.7 (d, ¹*J* = 248.7 Hz), 157.6 (d, ⁴*J* = 2.5 Hz), 157.4 (d, ⁴*J* = 2.9 Hz), 147.6, 144.6, 136.6 (d, ³*J* = 5.5 Hz), 131.9 (d, ³*J* = 9.2 Hz), 129.5, 120.4 (d, ²*J* = 25.8 Hz), 118.7 (d, ³*J* = 6.4 Hz), 118.2, 113.4, 110.8 (d, ²*J* = 21.7 Hz), 93.2 (d, ¹*J* = 174.5 Hz), 48.5 (d, ²*J* = 22.4 Hz).

¹⁹F NMR (376 MHz, CDCl₃): δ –112.80, –191.35.

HRMS (ESI): exact mass calculated for $[M+H]^+$ (C₁₇H₁₅F₂N₂) requires *m/z* 285.1198, found *m/z* 285.1190.

The enantiomeric purity of the product was determined by HPLC analysis: 94:6 e.r. (Chiralpak IA, hexane/*i*-PrOH = 50/50, flow rate 0.5 mL/min, λ = 250 nm), t_r (major) = 11.4 min, t_r (minor) = 12.1 min;

 $[\alpha]_{D}^{20} = +40.0 \ (c \ 0.10, \ CHCl_{3}).$





(R)-N-(2-(6-Bromoquinolin-2-yl)-2-fluoroethyl)aniline 7p



Prepared according to General Procedure B using 6-bromo-2-(1-fluorovinyl)quinoline (25.2 mg, 0.10 mmol, 1.0 equiv), aniline (27 μ L, 0.30 mmol, 3.0 equiv), (S)-TRIP catalyst (15.1 mg, 0.02 mmol, 20 mol%), and CPME (200 μ L, 0.5 M) at -10 °C for 3 d. The reaction mixture was subjected to the purification outlined in General Procedure B (silica gel, EtOAc:petroleum ether, 5:95 to 10:100) to afford the desired product as a pale brown oil (33.1 mg, 96%).

 v_{max} (film): 1603, 1508, 1491, 1059, 831, 750, 692 cm⁻¹.

¹**H** NMR (400 MHz, CDCl₃): δ 8.13 (d, J = 8.5 Hz, 1H), 8.00 (d, J = 2.2 Hz, 1H), 7.96 (d, J = 9.0 Hz, 1H), 7.81 (dd, J = 9.0, 2.2 Hz, 1H), 7.65 (d, J = 8.5 Hz, 1H), 7.19 (t, J = 7.8 Hz, 2H), 6.78 – 6.69 (m, 3H), 5.87 (ddd, ² J_{HF} = 48.7 Hz, J = 7.3, 3.6 Hz, 1H), 4.25 (s, 1H), 3.95 (ddd, ³ J_{HF} = 26.4 Hz, ² J_{HH} = 14.1 Hz, J = 3.6 Hz, 1H), 3.71 (ddd, ³ J_{HF} = 20.9 Hz, ² J_{HH} = 14.1 Hz, J = 7.3 Hz, 1H).

¹³C NMR (101 MHz, CDCl₃): δ 158.6 (d, ²*J* = 24.8 Hz), 147.5, 146.1 (d, ⁴*J* = 2.4 Hz), 136.2, 133.5, 131.1, 129.9, 129.5, 128.9, 120.8, 118.8 (d, ³*J* = 6.6 Hz), 118.3, 113.4, 93.2 (d, ¹*J* = 174.8 Hz), 48.5 (d, ²*J* = 22.2 Hz).

¹⁹F NMR (**376** MHz, CDCl₃): δ –191.78.

HRMS (ESI): exact mass calculated for $[M+H]^+$ (C₁₇H₁₅BrFN₂) requires *m/z* 345.0397, found *m/z* 345.0393.

The enantiomeric purity of the product was determined by HPLC analysis: 93:7 e.r. (Chiralpak IA, hexane/*i*-PrOH = 50/50, flow rate 0.5 mL/min, λ = 250 nm), t_r (major) = 12.7 min, t_r (minor) = 13.4 min;





(R)-N-(2-(4-Bromoquinolin-2-yl)-2-fluoroethyl)aniline 7q



Prepared according to General Procedure A using 4-bromo-2-(1-fluorovinyl)quinoline (25.2 mg, 0.10 mmol, 1.0 equiv), aniline (27 μ L, 0.30 mmol, 3.0 equiv), (*S*)-TRIP catalyst (15.1 mg, 0.02 mmol, 20 mol%), and THF (200 μ L, 0.5 M). The reaction mixture was subjected to the purification outlined in General Procedure A (silica gel, EtOAc:petroleum ether, 5:95 to 10:90) to afford the desired product as a pale yellow solid (33.1 mg, 96%).

 v_{max} (film): 1603, 1508, 1491, 1319, 1261, 1186, 1059, 880, 831, 750, 692 cm⁻¹.

¹**H NMR (500 MHz, CDCl₃):** δ 8.20 (dd, J = 8.4, 1.4 Hz, 1H), 8.09 (d, J = 8.4 Hz, 1H), 7.94 (d, J = 1.5 Hz, 1H), 7.80 (ddd, J = 8.4, 6.9, 1.4 Hz, 1H), 7.66 (ddd, J = 8.3, 6.9, 1.2 Hz, 1H), 7.19 (t, J = 7.7 Hz, 2H), 6.78 – 6.71 (m, 3H), 5.86 (ddd, ²J_{HF} = 48.6 Hz, J = 7.3, 3.6 Hz, 1H), 3.95 (ddd, ³J_{HF} = 26.4 Hz, ²J_{HH} = 14.2 Hz, J = 3.6 Hz, 1H), 3.78 – 3.66 (m, 1H).

¹³C NMR (126 MHz, CDCl₃): δ 158.0 (d, ²*J* = 25.0 Hz), 148.1, 147.5, 135.4, 131.0, 129.8, 129.5, 128.2, 127.4, 127.0, 122.0 (d, ³*J* = 7.5 Hz), 118.3, 113.5, 92.7 (d, ¹*J* = 175.8 Hz), 48.5 (d, ²*J* = 21.9 Hz).

¹⁹F NMR (470 MHz, CDCl₃): δ –192.02.

HRMS (ESI): exact mass calculated for $[M+H]^+$ (C₁₇H₁₅BrFN₂) requires *m/z* 345.0397, found *m/z* 345.0394.

The enantiomeric purity of the product was determined by HPLC analysis: 98:2 e.r. (Chiralcel OJ-H, hexane/*i*-PrOH = 50/50, flow rate 1.0 mL/min, $\lambda = 250$ nm), t_r (major) = 24.4 min, t_r (minor) = 20.5 min;

 $[\alpha]_{D}^{20} = +30.7 \ (c \ 0.27, \ CHCl_3).$



(R)-N-(2-Fluoro-2-(quinoxalin-2-yl)ethyl)aniline 7r



Prepared according to General Procedure B using 2-(1-fluorovinyl)quinoxaline (17.4 mg, 0.10 mmol, 1.0 equiv), aniline (27 μ L, 0.30 mmol, 3.0 equiv), (S)-TRIP catalyst (15.1 mg, 0.02 mmol, 20 mol%),

and CPME (200 μ L, 0.5 M) at -10 °C for 3 d. The reaction mixture was subjected to the purification outlined in General Procedure B (silica gel, EtOAc:petroleum ether, 5:95 to 10:90) to afford the desired product as a pale brown oil (23.3 mg, 87%)

v_{max} (film): 1603, 1495, 1063, 750, 692 cm⁻¹.

¹**H NMR (400 MHz, CDCl₃):** δ 9.07 (s, 1H), 8.17 – 8.08 (m, 2H), 7.81 (qd, J = 7.0, 3.4 Hz, 2H), 7.19 (t, J = 7.9 Hz, 2H), 6.78 – 6.70 (m, 3H), 5.97 (ddd, ² $J_{\rm HF}$ = 48.1 Hz, J = 7.1, 3.5 Hz, 1H), 4.00 (ddd, ³ $J_{\rm HF}$ = 26.1 Hz, ² $J_{\rm HH}$ = 14.4 Hz, J = 3.6 Hz, 1H), 3.79 (ddd, ³ $J_{\rm HF}$ = 21.3 Hz, ² $J_{\rm HH}$ = 14.4 Hz, J = 7.1 Hz, 1H).

¹³C NMR (101 MHz, CDCl₃): δ 152.4 (d, ²*J* = 24.2 Hz), 147.3, 142.8 (d, ³*J* = 7.3 Hz), 142.5, 141.5, 130.7, 130.4, 129.6, 129.5, 129.4, 118.5, 113.5, 92.3 (d, ¹*J* = 174.1 Hz), 48.2 (d, ²*J* = 22.0 Hz).

¹⁹F NMR (376 MHz, CDCl₃): δ –193.73.

HRMS (ESI): exact mass calculated for $[M+H]^+$ (C₁₆H₁₅FN₃) requires m/z 268.1245, found m/z 268.1243.

The enantiomeric purity of the product was determined by HPLC analysis: 92:8 e.r. (Chiralcel OJ-H, hexane/*i*-PrOH = 50/50, flow rate 0.5 mL/min, λ = 250 nm), t_r (major) = 36.3 min, t_r (minor) = 42.2 min;

 $[\alpha]_{D}^{20} = +5.4 \ (c \ 0.13, \text{CHCl}_3).$





(R)-N-(2-(Benzo[d]thiazol-2-yl)-2-fluoroethyl)aniline 7s



Prepared according to General Procedure B using 2-(1-fluorovinyl)benzo[*d*]thiazole (17.9 mg, 0.10 mmol, 1.0 equiv), aniline (27 μ L, 0.30 mmol, 3.0 equiv), (*S*)-TRIP catalyst (15.1 mg, 0.02 mmol, 20 mol%), and CPME (200 μ L, 0.5 M) at -10 °C for 3 d. The reaction mixture was subjected to the purification outlined in General Procedure B (silica gel, EtOAc:petroleum ether, 5:95 to 10:90) to afford the desired product as a pale yellow solid (20.3 mg, 75%).

 v_{max} (film): 2357, 1603, 1508, 1317, 1260, 1061, 872, 754, 692 cm⁻¹.

¹**H NMR (400 MHz, CDCl₃):** δ 8.07 (d, J = 8.2 Hz, 1H), 7.94 (d, J = 7.9 Hz, 1H), 7.53 (ddd, J = 8.3, 7.2, 1.3 Hz, 1H), 7.44 (ddd, J = 8.3, 7.2, 1.2 Hz, 1H), 7.22 (dd, J = 8.6, 7.3 Hz, 2H), 6.83 – 6.70 (m, 3H), 6.02 (ddd, ² J_{HF} = 48.0 Hz, J = 7.2, 3.7 Hz, 1H), 4.02 (ddd, ³ J_{HF} = 26.1 Hz, ² J_{HH} = 14.5 Hz, J = 3.7 Hz, 1H), 3.80 (ddd, ³ J_{HF} = 19.7 Hz, ² J_{HH} = 14.5 Hz, J = 7.2 Hz, 1H).

¹³C NMR (101 MHz, CDCl₃): δ 168.0 (d, ²*J* = 28.0 Hz), 153.1, 147.0, 134.9, 129.6, 126.6, 125.7, 123.6, 122.0, 118.7, 113.6, 90.7 (d, ¹*J* = 173.9 Hz), 48.4 (d, ²*J* = 22.0 Hz).

¹⁹F NMR (377 MHz, CDCl₃): δ –181.92.

HRMS (ESI): exact mass calculated for $[M+H]^+$ (C₁₅H₁₄FN₂S) requires *m/z* 273.0856, found *m/z* 273.0853.

The enantiomeric purity of the product was determined by HPLC analysis: 96:4 e.r. (Chiralcel OJ-H, hexane/*i*-PrOH = 50/50, flow rate 0.5 mL/min, λ = 250 nm), t_r (major) = 39.7 min, t_r (minor) 47.3 = min;



Methyl (R)-6-(1-fluoro-2-(phenylamino)ethyl)nicotinate 7t



Prepared according to General Procedure B using methyl 6-(1-fluorovinyl)nicotinate (18.1 mg, 0.10 mmol, 1.0 equiv), aniline (27 μ L, 0.30 mmol, 3.0 equiv), (S)-TRIP catalyst (15.1 mg, 0.02 mmol, 20 mol%), and CPME (200 μ L, 0.5 M) at rt for 3 d. The reaction mixture was subjected to the purification outlined in General Procedure B (silica gel, EtOAc:petroleum ether, 5:95 to 10:90) to afford the desired product as a pale brown oil (6.8 mg, 25%).

 v_{max} (film): 1728, 1601, 1506, 1437, 1294, 1119, 750, 694 cm⁻¹.

¹**H NMR (400 MHz, CDCl₃):** δ 9.20 – 9.19 (m, 1H), 8.35 (dd, *J* = 8.2, 2.1 Hz, 1H), 7.60 (d, *J* = 8.2 Hz, 1H), 7.25 – 7.13 (m, 2H), 6.80 – 6.65 (m, 3H), 5.78 (ddd, ²*J*_{HF} = 48.4 Hz, *J* = 7.2, 3.3 Hz, 1H), 4.03 – 3.82 (m, 4H), 3.61 (ddd, ³*J*_{HF} = 21.3 Hz, ²*J*_{HH} = 14.3 Hz, *J* = 7.2 Hz, 1H).

¹³C NMR (101 MHz, CDCl₃): δ 165.6, 162.0 (d, ²*J* = 24.7 Hz), 150.4 (d, ⁴*J* = 2.7 Hz), 147.4, 138.2, 129.5, 125.6, 119.8 (d, ³*J* = 7.4 Hz), 118.3, 113.4, 92.7 (d, ¹*J* = 175.3 Hz), 52.6, 48.4 (d, ²*J* = 21.6 Hz).

¹⁹F NMR (**376** MHz, CDCl₃): δ –193.31.

HRMS (ESI): exact mass calculated for $[M+H]^+$ (C₁₅H₁₆FN₂O₂) requires *m/z* 275.1190, found *m/z* 275.1190.

The enantiomeric purity of the product was determined by HPLC analysis: 88:12 e.r. (Chiralpak IA, hexane/*i*-PrOH = 50/50, flow rate 0.5 mL/min, λ = 250 nm), t_r (major) = 13.0 min, t_r (minor) = 14.8 min;



 $[\alpha]_{D}^{20} = +2.95 \ (c \ 0.88, \text{CHCl}_3).$



(R)-N-(2-Fluoro-2-(isoquinolin-1-yl)ethyl)aniline 7u



Prepared according to General Procedure B using 1-(1-fluorovinyl)isoquinoline (17.3 mg, 0.10 mmol, 1.0 equiv), aniline (27 μ L, 0.30 mmol, 3.0 equiv), (*S*)-TRIP catalyst (15.1 mg, 0.02 mmol, 20 mol%), and CPME (200 μ L, 0.5 M) at -10 °C for 3 d. The reaction mixture was subjected to the purification outlined in General Procedure B (silica gel, EtOAc:petroleum ether, 5:95 to 10:90) to afford the desired product as a pale brown oil (16.3 mg, 61%).

 v_{max} (film): 1603, 1504, 829, 748, 692 cm⁻¹.

¹**H** NMR (400 MHz, CDCl₃): δ 8.56 (d, J = 5.7 Hz, 1H), 8.31 (d, J = 8.0 Hz, 1H), 7.88 (d, J = 8.2 Hz, 1H), 7.77 – 7.60 (m, 3H), 7.25 – 7.16 (m, 2H), 6.79 – 6.69 (m, 3H), 6.37 (ddd, ² J_{HF} = 48.4, J = 6.9, 5.2 Hz, 1H), 4.33 (s, 1H), 4.15 – 3.93 (m, 2H).

¹³C NMR (101 MHz, CDCl₃): δ 155.2 (d, ²*J* = 18.6 Hz), 147.6, 141.7, 136.8, 130.4, 129.5, 128.0, 127.7, 126.9, 124.9 (d, ³*J* = 4.8 Hz), 122.0, 118.1, 113.4, 90.8 (d, ¹*J* = 173.5 Hz), 46.9 (d, ²*J* = 24.1 Hz).

¹⁹F NMR (376 MHz, CDCl₃): δ –180.92.

HRMS (ESI): exact mass calculated for $[M+H]^+$ (C₁₇H₁₆FN₂) requires *m/z* 267.1292, found *m/z* 267.1290.

The enantiomeric purity of the product was determined by HPLC analysis: 62:38 e.r. (Chiralpak IA, hexane/*i*-PrOH = 50/50, flow rate 0.5 mL/min, λ = 250 nm), t_r (major) = 14.8 min, t_r (minor) = 23.9 min;

 $[\alpha]_{\rm D}^{20} = +2.00 \ (c \ 0.10, \ {\rm CHCl}_3).$



(S)-N-(2-Fluoro-2-(quinolin-4-yl)ethyl)aniline 7v



Prepared according to General Procedure B using 4-(1-fluorovinyl)quinoline (17.3 mg, 0.10 mmol, 1.0 equiv), aniline (27 μ L, 0.30 mmol, 3.0 equiv), (S)-TRIP catalyst (15.1 mg, 0.02 mmol, 20 mol%), and CPME (200 μ L, 0.5 M) at rt for 3 d. The reaction mixture was subjected to the purification outlined in General Procedure B (silica gel, EtOAc:petroleum ether, 5:95 to 10:90) to afford the desired product as a pale yellow solid (17.9 mg, 68%).

 v_{max} (film): 2361, 1601, 1509, 1323, 1250, 1069, 752 cm⁻¹.

¹**H** NMR (400 MHz, CDCl₃): δ 8.96 (d, J = 4.4 Hz, 1H), 8.20 (dt, J = 8.4, 1.1 Hz, 1H), 7.92 (dt, J = 8.5, 0.9 Hz, 1H), 7.77 (ddd, J = 8.4, 6.9, 1.4 Hz, 1H), 7.62 (ddd, J = 8.3, 6.9, 1.3 Hz, 1H), 7.55 (dd, J = 4.5, 0.8 Hz, 1H), 7.31 – 7.12 (m, 2H), 6.79 (tt, J = 7.3, 1.1 Hz, 1H), 6.76 – 6.65 (m, 2H), 6.50 – 6.25 (m, 1H), 4.17 (s, 1H), 3.81 (ddd, ³ J_{HF} = 29.9 Hz, ² J_{HH} = 14.4 Hz, J = 3.0 Hz, 1H), 3.61 (ddd, ³ J_{HF} = 18.3 Hz, ² J_{HH} = 14.4 Hz, J = 8.1 Hz, 1H).

¹³C NMR (101 MHz, CDCl₃): δ 150.2, 148.2, 147.1, 143.0 (d, ²*J* = 19.2 Hz), 130.7, 129.60, 129.53, 127.29, 122.41, 118.64, 117.68, 117.57, 113.45, 89.90 (d, ¹*J* = 175.4 Hz), 49.54 (d, ²*J* = 23.6 Hz).

¹⁹F NMR (377 MHz, CDCl₃): δ –190.24.

HRMS(ESI): exact mass calculated for $[M+H]^+$ (C₁₇H₁₆FN₂) requires m/z 267.1292, found m/z 267.1285.

The enantiomeric purity of the product was determined by HPLC analysis: 50:50 e.r. (Chiralpak IA, hexane/*i*-PrOH = 50/50, flow rate 0.5 mL/min, $\lambda = 250$ nm), t_r (major) = 5.7 min, t_r (minor) = 6.9 min;





(R)-N-(2-(8-Chloroquinolin-2-yl)-2-fluoroethyl)aniline 7w



Prepared according to General Procedure B using 2-(1-fluorovinyl)-8-chloroquinoline (10.4 mg, 0.05 mmol, 1.0 equiv), aniline (14 μ L, 0.15 mmol, 3.0 equiv), (S)-TRIP catalyst (7.5 mg, 0.01 mmol, 20 mol%), and CPME (100 μ L, 0.5 M) at 40 °C. The reaction mixture was subjected to the purification outlined in General Procedure B (silica gel, EtOAc:petroleum ether, 5:95 to 10:90) to afford the desired product as a pale brown oil (9.5 mg, 50%).

 v_{max} (film): 1601, 1501, 841, 752, 692, 669 cm⁻¹.

¹**H** NMR (400 MHz, CDCl₃): δ 8.25 (d, J = 8.5 Hz, 1H), 7.87 (dd, J = 7.5, 1.3 Hz, 1H), 7.75 (ddd, J = 16.5, 8.4, 1.6 Hz, 2H), 7.49 (dd, J = 8.2, 7.5 Hz, 1H), 7.24 – 7.15 (m, 2H), 6.81 – 6.69 (m, 3H), 5.95 (ddd, ² $_{JHF}$ = 48.1 Hz, J = 6.2, 5.0 Hz, 1H), 4.71 (s, 1H), 4.03 – 3.77 (m, 2H).

¹³C NMR (101 MHz, CDCl₃): δ 159.4 (d, ²*J* = 25.7 Hz), 147.8, 143.6, 137.7, 133.7, 130.1, 129.5, 129.0, 126.9, 126.9, 118.7 (d, ³*J* = 6.9 Hz), 118.1, 113.5, 92.7 (d, ¹*J* = 175.2 Hz), 48.4 (d, ²*J* = 23.1 Hz).

¹⁹F NMR (376 MHz, CDCl₃): δ –191.99.

HRMS (ESI): exact mass calculated for $[M+H]^+$ (C₁₇H₁₅N₂ClF) requires *m/z* 301.0902, found *m/z* 301.0898.

The enantiomeric purity of the product was determined by HPLC analysis: 51:49 e.r. (Chiralpak IA, hexane/*i*-PrOH = 50/50, flow rate 0.5 mL/min, $\lambda = 250$ nm), t_r (major) = 10.5 min, t_r (minor) = 10.1 min;



2-(3,3,3-Trifluoroprop-1-en-2-yl)quinoline 10



This compound was prepared according to an adapted literature procedure.⁸

An oven-dried round 100 mL round bottom flask was charged with Mg turnings (262 mg, 10.8 mmol, 1.2 equiv), capped and purged with N₂. Then THF (18 mL, 0.5 M) and freshly distilled trimethylborate (1.50 mL, 13.5 mmol, 1.5 equiv) were added sequentially and the mixture was allowed to stir at rt for 5 min. 2-Bromo-1,1,1-trifluoropropene (0.96 mL, 9.00 mmol, 1.0 equiv) was then added dropwise over 5 min, then the reaction was stirred for 4 h at rt. The reaction was quenched using 6 M HCl (50 mL) and the solution was left to stir for 5 min. The organic layer was then separated and the aqueous layer was extracted with Et₂O (3×20 mL). The combined organic extracts were washed with brine (50 mL), dried over NaSO₄, filtered, and concentrated *in vacuo*. Formation of the boronic acid was confirmed *via* ¹¹B NMR, then the crude was used directly in the next step.

NB. Calculations based upon quantitative conversion to boronic acid in the previous step. An ovendried 2-necked 100 mL round bottomed flask equipped with a reflux condenser was charged with $Pd(OAc)_2$ (50.5 mg, 0.225 mmol, 5 mol%), SPhos (185 mg, 0.45 mmol, 10 mol%), 2-bromoquinoline (936 mg, 4.50 mmol, 1.0 equiv), the crude boronic acid (9.00 mmol, 2.0 equiv), and K₃PO₄ (2.87 g, 13.5 mmol, 3.00 equiv). The vessel was capped and purged with N₂. THF (22.5 mL, 0.2 M) and water (405 µL, 22.5 mmol, 5.0 equiv) were then added to the mixture sequentially. The reaction was then heated to 50 °C for 16 h. The reaction mixture was then cooled to rt, filtered through Celite, eluting with EtOAc and concentrated *in vacuo*. Purification of the crude *via* flash chromatography (silica gel, EtOAc:petroleum ether, 10:90) gave the desired product as a pale yellow oil (102 mg, 9%).

NB. Due to the reactive nature of this compound, an analytically pure sample was not obtained, data reported as observed. The compound was used directly in the next step.

 v_{max} (film): 2361, 2342, 1504, 1323, 1196, 1126, 1096, 1069, 907, 833, 729, 648 cm⁻¹.

¹**H NMR (400 MHz, CDCl₃):** δ 8.20 (d, J = 8.7 Hz, 1H), 8.11 (d, J = 8.4 Hz, 1H), 7.83 (d, J = 8.1 Hz, 1H), 7.74 (ddd, J = 8.4, 6.9, 1.4 Hz, 1H), 7.65 – 7.60 (m, 1H), 7.56 (ddd, J = 8.1, 6.9, 1.1 Hz, 1H), 6.68 (q, ${}^{4}J_{\text{HF}}$ = 1.8 Hz, 1H), 6.25 (q, ${}^{4}J_{\text{HF}}$ = 1.4 Hz, 1H).

¹³C NMR (126 MHz, CDCl₃): δ 151.0, 148.0, 138.5 (q, ²*J* = 27.7 Hz), 137.0, 130.2, 130.0, 127.8, 127.6, 127.3, 124.5 (q, ¹*J* = 273.4 Hz), 123.3 (q, ³*J* = 6.3 Hz), 119.2.

¹⁹F NMR (470 MHz, CDCl₃): δ –63.61.

HRMS (ESI): exact mass calculated for $[M+H]^+$ (C₁₂H₉F₃N) requires *m/z* 224.0682, found *m/z* 224.0677.

(R)-N-(3,3,3-Trifluoro-2-(quinolin-2-yl)propyl)aniline 11



Prepared according to General Procedure B using 2-(3,3,3-trifluoroprop-1-en-2-yl)quinoline (11.2 mg, 0.05 mmol, 1.0 equiv), aniline (14 μ L, 0.15 mmol, 3.0 equiv), (*S*)-TRIP catalyst (37.6 mg, 0.05 mmol, 1.0 equiv), and CPME (200 μ L, 0.25 M) at -50 °C for 3 d. The reaction mixture was subjected to the purification outlined in General Procedure B (silica gel, EtOAc:petroleum ether, 5:95 to 10:90) to afford the desired product as a pale yellow solid (11.5 mg, 73%).

 v_{max} (film): 2361, 2342, 1601, 1504, 1315, 1254, 1165, 1111, 826, 752, 694 cm⁻¹.

¹**H** NMR (500 MHz, CDCl₃): δ 8.18 – 8.14 (m, 2H), 7.85 (dd, J = 8.2, 1.4 Hz, 1H), 7.77 (ddd, J = 8.4, 6.9, 1.5 Hz, 1H), 7.59 (ddd, J = 8.1, 6.9, 1.2 Hz, 1H), 7.40 (d, J = 8.4 Hz, 1H), 7.20 – 7.14 (m, 2H), 6.73 (tt, J = 7.3, 1.1 Hz, 1H), 6.59 (dt, J = 7.7, 1.0 Hz, 2H), 4.20 – 3.82 (m, 4H).

¹³C NMR (126 MHz, CDCl₃): δ 153.4, 148.0, 147.0, 137.1, 130.1, 129.7, 129.5, 127.7, 127.7, 127.2, 126.1 (q, ${}^{1}J = 280.5$ Hz), 122.1, 118.2, 113.2, 51.1 (q, ${}^{2}J = 25.0$ Hz), 41.9.

¹⁹F NMR (470 MHz, CDCl₃): δ –67.02.

HRMS (ESI): exact mass calculated for $[M+H]^+$ (C₁₈H₁₆F₃N₂) requires m/z 317.1260, found m/z 317.1251.

The enantiomeric purity of the product was determined by HPLC analysis: 90:10 e.r. (Chiralpak IA, hexane/*i*-PrOH = 50/50, flow rate 1.0 mL/min, $\lambda = 250$ nm), t_r (major) = 9.1 min, t_r (minor) = 11.6 min;







N-(2-Fluoro-2-(quinolin-2-yl)ethyl)-N-phenylacetamide 16



Prepared according to literature procedure.9

A 10 mL microwave vial was charged with *N*-(2-fluoro-2-(quinolin-2-yl)ethyl)aniline (151 mg, 0.57 mmol, 1.0 equiv). The vial was capped and purged with N₂. Dry CH₂Cl₂ (1 mL) and Ac₂O (54 μ L, 0.57 mmol, 1.0 equiv) were added to the vessel and the reaction mixture was allowed to stir at rt for 16 h. The reaction was then quenched with 2 M HCl (1 mL) and the aqueous phase was extracted with CH₂Cl₂ (2 × 5 mL). The combined organic phases were dried over Na₂SO₄, filtered, and concentrated *in vacuo*. Purification of the crude *via* flash chromatography (silica gel, EtOAc:petroleum ether, 5:95 to 10:90) gave the desired product as a pale yellow oil (51.0 mg, 29%).

 v_{max} (film): 1659, 1597, 1497, 1427, 1389, 1300, 1281, 1072, 1026, 837, 756, 702 cm⁻¹.

¹**H NMR (500 MHz, CDCl₃):** δ 8.21 (d, *J* = 8.5 Hz, 1H), 8.03 (d, *J* = 8.5 Hz, 1H), 7.82 (d, *J* = 8.1 Hz, 1H), 7.71 (t, *J* = 7.7 Hz, 1H), 7.63 (d, *J* = 8.2 Hz, 1H), 7.55 (t, *J* = 7.5 Hz, 1H), 7.43 (t, *J* = 7.5 Hz, 2H), 7.35 (dd, *J* = 23.7, 7.4 Hz, 3H), 5.99 – 5.84 (m, 1H), 4.42 – 4.26 (m, 2H), 1.90 (s, 3H).

¹³C NMR (126 MHz, CDCl₃): δ 171.2, 157.4 (d, ²*J* = 22.2 Hz), 147.5, 143.2, 137.2, 130.0, 129.9, 129.4, 128.6, 128.3, 127.9, 127.8, 127.0, 118.3 (d, ³*J* = 5.6 Hz), 92.0 (d, ¹*J* = 176.9 Hz), 53.2 (d, ²*J* = 22.7 Hz), 23.0.

¹⁹F NMR (470 MHz, CDCl₃): δ –189.42.

HRMS (ESI): exact mass calculated for $[M+H]^+$ (C₁₉H₁₈FN₂O) requires *m/z* 309.1398, found *m/z* 309.1388.

8. References

1. Armarego, W. L. F.; Chai, C. Purification of Laboratory Chemicals, 7th ed., Elsevier, Oxford, 2013.

2. T. Hanamoto, T. Kobayashi, J. Org. Chem 2003, 68, 6354-6359.

3. T. Dorn, C. Janiak, K. Abu-Shandi, CrystEngComm 2005, 7, 633-641.

4. Gaussian 09, Revision C.01, M. J. Frisch, G. W. Trucks, H. B. Schlegel, G. E. Scuseria, M. A. Robb, J. R. Cheeseman, G. Scalmani, V. Barone, G. A. Petersson, H. Nakatsuji, X. Li, M. Caricato, A. Marenich, J. Bloino, B. G. Janesko, R. Gomperts, B. Mennucci, H. P. Hratchian, J. V. Ortiz, A. F. Izmaylov, J. L. Sonnenberg, D. Williams-Young, F. Ding, F. Lipparini, F. Egidi, J. Goings, B. Peng, A. Petrone, T. Henderson, D. Ranasinghe, V. G. Zakrzewski, J. Gao, N. Rega, G. Zheng, W. Liang, M. Hada, M. Ehara, K. Toyota, R. Fukuda, J. Hasegawa, M. Ishida, T. Nakajima, Y. Honda, O. Kitao, H. Nakai, T. Vreven, K. Throssell, J. A. Montgomery, Jr., J. E. Peralta, F. Ogliaro, M. Bearpark, J. J. Heyd, E. Brothers, K. N. Kudin, V. N. Staroverov, T. Keith, R. Kobayashi, J. Normand, K. Raghavachari, A. Rendell, J. C. Burant, S. S. Iyengar, J. Tomasi, M. Cossi, J. M. Millam, M. Klene, C. Adamo, R. Cammi, J. W. Ochterski, R. L. Martin, K. Morokuma, O. Farkas, J. B. Foresman, and D. J. Fox, Gaussian, Inc., Wallingford CT, 2016.

5. Ignacio Funes-Ardoiz, Robert S. Paton, GoodVibes: Version 2.0.3, Zenodo, 2018.

6. D, Wang, Y. Wang, J. Zhao, L. Li, L. Miao, D. Wang, H. Sun, P. Yu, *Tetrahedron* **2016**, *72*, 5762–5768.

7. S. E. Wengryniuk, A. Weickgenannt, C. Reiher, N. A. Strotman, K. Chen, M. D. Eastgate, P. S. Baran Org. Lett. 2013, 15, 792–795.

8. B. Jiang, Q.-F. Wang, C.-G. Yang, M. Xu Tetrahedron Lett. 2001, 42, 4083-4085.

9. A. Romanens, G. Bélanger, Org. Lett. 2015, 17, 322-325.

9. NMR Spectra ¹H NMR of 5a







H.0.1

5.5

6.0

5.0

4.5 f1 (ppm) 4.0

0.94<u>4</u> 0.94<u>4</u> 0.95<u>4</u> 1.05<u>4</u> 1.05<u>4</u>

7.5

7.0

6.5

8.0

8.5

9.0







10 0 -10 -20 -30 -40 -50 -60 -70 -80 -90 -100 -110 -120 -130 -140 -150 -160 -170 -180 -190 -200 -210 -220 -230 -240 -25(f1 (ppm)









S70

¹³C NMR of 5d



10 0 -10 -20 -30 -40 -50 -60 -70 -80 -90 -100 -110 -120 -130 -140 -150 -160 -170 -180 -190 -200 -210 -220 -230 -240 -25(f1 (ppm)

¹H NMR of 5e $\sum_{\substack{5.12\\5.12}} \sum_{\substack{5.23\\5.84}} \sum_{\substack{5.28\\5.17\\5.12}}$ Br J١ 1.00-1 _____66.0 0.94 0.94 0.93 1.02 0.98 0.98 0.98 0.98 4.5 f1 (ppm) 8.0 8.5 7.5 7.0 5.0 4.0 3.5 3.0 2.5 2.0 9.0 6.5 6.0 5.5 1.5 1.0 0.5 0.0 ¹³C NMR of 5e

162.04 160.04	149.98 149.69 148.33 148.30	134.97 134.95 130.93 120.85 120.85 120.85	94.76 94.62
11	NK	インママ	\vee




S73





10	0	-10	-20	-30	-40	-50	-60	-70	-80	-90	-100	-110	-120	-130	-140	-150	-160	-170	-180	-190	-200	-210	-220	-230	-240	-250
												1	f1 (ppm	ı)												

¹H NMR of 5g







159.71 158.30 156.33 155.33 153.53 153.53 153.53	134.97	126.84 126.12 123.83 121.88	95.59 95.45
NIIL		SULL	Y





S76





-30 -40 -50 -60 -70 -80 -90 -100 -110 -120 -130 -140 -150 -160 -170 -180 -190 -200 -210 f1 (ppm)

¹H NMR of 5i







¹H NMR of 5j





10 0 -10 -20 -30 -40 -50 -60 -70 -80 -90 -100 -110 -120 -130 -140 -150 -160 -170 -180 -190 -200 -210 -220 -230 -240 -25(f1 (ppm)

¹H NMR of 5k









S82





-10 -20 -30 -40 -50 -60 -70 -80 -90 -100 -110 -120 -130 -140 -150 -160 -170 -180 -190 f1 (ppm)







¹³C NMR of 7c



-90 -100 -110 -120 f1 (ppm) -10 -20 -60 -70 -80 -30 -40 -50 -130 -140 -150 -160 -170 -180 -190

ī

¹H NMR of 7d









¹³C NMR of 7e



10 0 -10 -20 -30 -40 -50 -60 -70 -80 -90 -100 -110 -120 -130 -140 -150 -160 -170 -180 -190 -200 -210 -220 -230 -240 -250 f1 (ppm)



S90





----190.85





-----191.44



-90 -100 -110 -120 f1 (ppm) -10 -80 -20 -30 -40 -50 -60 -70 -130 -140 -150 -160 -170 -180 -190







S95





-90 -100 -110 -120 f1 (ppm) -10 -80 -20 -30 -40 -50 -60 -70 -130 -140 -150 -160 -170 -180 -190

¹H NMR of 7k







S99

-----190.65





-90 -100 -110 f1 (ppm) -10 -70 -20 -30 -40 -50 -60 -80 -120 -130 -150 -180 -140 -160 -170 -190





S102





10 0 -10 -20 -30 -40 -50 -60 -70 -80 -90 -100 -110 -120 -130 -140 -150 -160 -170 -180 -190 -200 -210 -220 -230 -240 -25(f1 (ppm)















¹³C NMR of 7p



10 0 -10 -20 -30 -40 -50 -60 -70 -80 -90 -100 -110 -120 -130 -140 -150 -160 -170 -180 -190 -200 -210 -220 -230 -240 -25(f1 (ppm)






¹³C NMR of 7r



10 0 -10 -20 -30 -40 -50 -60 -70 -80 -90 -100 -110 -120 -130 -140 -150 -160 -170 -180 -190 -200 -210 -220 -230 -240 -25(f1 (ppm)











-30 -40 -50 -60 -70 -80 -90 -100 -110 -120 -130 -140 -150 -160 -170 -180 -190 -200 -210 fl (ppm)









-30 -40 -50 -60 -70 -80 -90 -100 -110 -120 -130 -140 -150 -160 -170 -180 -190 -200 -210 fl (ppm)



S116



















¹H NMR of 16





10	0	-10	-20	-30	-40	-50	-60	-70	-80	-90	-100	-110	-120	-130	-140	-150	-160	-170	-180	-190	-200	-210	-220	-230	-240	-25(
												f	1 (ppm	ו)												

10. X-Ray Data

The datasets for all three compounds were collected using a Rigaku FR-X Ultrahigh Brilliance Microfocus RA generator/confocal optics with XtaLAB P200 diffractometer. The data for **7a** was collected at 125K with Cu radiation ($\lambda = 1.54187$ Å), whereas the data for **11** and **16** were collected at 93 K with Mo radiation ($\lambda = 0.71075$ Å). Intensity data were collected using ω steps accumulating area detector images spanning at least a hemisphere of reciprocal space. All data were corrected for Lorentz polarization effects. A multiscan absorption correction was applied by using CrysAlisPro. The structure of **7a** was solved using direct methods (SIR2011), whereas **11** and **16** were solved using dual space methods (SHELXT). The structures were refined by full-matrix least-squares against F² (SHELXL-2013). Non-hydrogen atoms were refined anisotropically, and hydrogen atoms were refined using a riding model, with the exception of H11 in **7a**, which was located via the electron density map. All calculations for **7a** were performed using the CrystalStructure interface and Olex2 for structures **11** and **16**. Selected crystallographic data are presented in Table 1. CCDC 1900849-1900851 contains the supplementary crystallographic data for this paper. The data can be obtained free of charge from the Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/structures.

	7a	16	11			
Crystal data						
Chemical formula	$C_{17}H_{15}FN_2$	C ₁₉ H ₁₇ FN ₂ O	$C_{18}H_{15}F_{3}N_{2}$			
$M_{ m r}$	266.32	308.35	316.32			
Crystal system, space group	Orthorhombic, $P2_12_12_1$	Monoclinic, C2/c	Monoclinic, <i>P</i> 2 ₁			
Temperature (K)	125	93	93			
a, b, c (Å)	5.44863 (10), 10.49560 (18), 23.5843 (4)	18.6107 (4), 7.75338 (14), 23.2547 (5)	10.1249 (3), 5.4916 (1), 13.3402 (5)			
α, β, γ (°)	90, 90, 90	90, 111.212 (2), 90	90, 93.978 (3), 90			
$V(Å^3)$	1348.71 (4)	3128.21 (12)	739.95 (4)			
Ζ	4	8	2			
Radiation type	Cu <i>K</i> α	Μο Κα	Μο <i>Κ</i> α			
μ (mm ⁻¹)	0.71	0.09	0.11			
Crystal size (mm)	$0.12 \times 0.10 \times 0.10$	$0.27 \times 0.18 \times 0.06$	$0.36 \times 0.09 \times 0.03$			
Data collection						
T_{\min}, T_{\max}	0.889, 0.932	0.881, 0.995	0.871, 1.000			
No. of measured, independent and observed reflections	15722, 2741, 2729	22904, 3460, 3247	8314, 2968, 2587			
R _{int}	0.019	0.018	0.022			
$(\sin\theta/\lambda)_{max}$ (Å ⁻¹)	0.628	0.664	0.660			

Refinement								
$R[F^2 > 2\sigma(F^2)],$ $wR(F^2), S$	0.027, 0.071, 1.09	0.040, 0.107, 1.02	0.039, 0.103, 1.06					
No. of reflections	2741	3460	2968					
No. of parameters	186	209	256					
No. of restraints	1	0	8					
$\Delta \rangle_{\rm max}, \Delta \rangle_{\rm min} \ ({ m e} \ { m \AA}^{-3})$	0.16, -0.18	0.50, -0.31	0.24, -0.23					
Absolute structure parameter	0.06 (4)	-	-0.2 (3)					

Computer programs: CrysAlis PRO 1.171.39.8d (Rigaku OD, 2015), CrysAlis PRO 1.171.40.29a (Rigaku OD, 2018), SIR2011 (Burla, et al., 2012), SHELXT Version 2014/4 (Sheldrick, 2014), SHELXT (Sheldrick, 2015), SHELXL Version 2014/7 (Sheldrick, 2008), SHELXL (Sheldrick, 2015), Olex2 (Dolomanov et al., 2009), CrystalStructure 4.2 (Rigaku, 2015), CrystalStructure 4.3 (Rigaku, 2018).